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ABSTRACT 
The placenta is formed early in pregnancy and plays a crucial role during its short 
existence, providing nutrients, hormones, and protection throughout pregnancy. For the placenta 
to function and develop properly, precise spatiotemporal expression of genes is critical.  
Abnormal gene expression can lead to adverse pregnancy outcomes and disease such as 
preeclampsia, hyperemesis gravidarium, placental abruption, and miscarriage. However, 
placental gene regulatory networks, that when disrupted could contribute to such outcomes, are 
poorly understood.  
Using the mouse as a model, we generated and analyzed several next generation 
sequencing datasets to better understand transcriptional regulation in the placenta. First, we 
generated chromatin accessibility data and integrated it with transcriptomic data to identify gene 
networks associated with important aspects of placental function, as well as gain insights into 
potential regulatory mechanisms of such genes. We also developed a pipeline for identifying 
genes important for development by analyzing their expression and promoter accessibility. Next, 
we generated epigenetic data, allowing us to identify cis-regulatory regions genome-wide and 
predict their biological role during a critical stage of development, when abnormal gene 
expression commonly causes embryonic lethality. Lastly, we were able to identify a novel 
angiogenic role for the PLAGL1 transcription factor within the placenta. Combining 
transcriptomic data with enhancer marks, we were able to computational predict that PLAGL1 
regulated enhancers targeting genes involved in blood vessel development. We then performed 
several molecular experiments in order to verify such predictions.  
xiv 
Each aspect of this work furthers our knowledge on placental gene regulation by 
identifying regulatory regions, their targets, and their controlling transcription factors which may 






CHAPTER 1.    GENERAL INTRODUCTION  
Understanding the intricate, complicated way our bodies and organs work has been a goal 
of scientists for generations. There has been a plethora of research aimed at many important 
organs that allow our body to function properly. Within the last sixty years several thousands of 
studies have been published on the heart, brain, liver, pancreas, and spleen. Although the 
importance of the organs comprising our digestive, endocrine, immune, and respiratory systems 
cannot be overstated, the placenta is an equally important organ that is less frequently in the 
research spotlight [Figure 1.1]. In order to better understand the development, function, and 
structure of the placenta, the Human Placenta Project[1] was initiated in 2014. Although this has 












Figure 1.1. Publications of major organs from 1960-2019. The number of publications every 15 
years from 1960 to 2019 for the brain, heart, liver, pancreas, spleen and placenta. Publication 
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The placenta plays pivotal roles in the maintenance of pregnancy and development of the 
embryo. The placenta has a multitude of roles throughout pregnancy including acting as the 
digestive, endocrine, immune and respiratory systems for the embryo while it develops [Figure 
1.2]. One of the many important roles of the placenta is to regulate nutrient transport from 
maternal blood to fetal blood. Nutrient transport across the placenta is affected by the amount of 
area for exchange to occur, blood flow to and from the placenta, and placental metabolism. 
Nutrients are transported across the maternofetal barrier (described in detail later) via many 
different mechanisms including passive diffusion and active transport. For example, amino acids 
are transported via active transporters while some fatty acids pass by diffusion[2].  Glucose, on 
the other hand is transported through carrier-mediated diffusion by glucose transporter proteins 
expressed within the placenta[2]. The placenta also has demands that are separate from the fetus, 
requiring energy to support protein synthesis and nutrient transport, consuming some of the 
oxygen and glucose received from maternal blood[2,3]. These nutrients and oxygen are delivered 
to the placenta by the maternal blood, and therefore, obstructions in blood flow will also  alter 
the amount of material passed on to the fetus[4].  
Other material is not passed along to the fetus, not because it is used by the placenta, but 
in order to protect the vulnerable fetus. For example, cortisol, which may have harmful effects on 
the fetus, is oxidized to form inactive cortisone[5]. Several transporters within the placenta also 
work to protect the fetus, including phosphor-glycoprotein and breast cancer resistance protein, 
which prevent xenobiotics from reaching the fetus[6].  
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Figure 1.2. Functions of the placenta.Diagram of four major roles of the placenta – protection, 
hormone production, nutrition, and gas exchange. 
 
Another critical role of the placenta is the production of hormones. Several hormones, or 
hormone-like proteins expressed by the placenta, including placental growth hormone and 
placental lactogens, are important throughout pregnancy. In the earlier stages of pregnancy, they 
are responsible for increasing maternal food consumption and contributing to maternal insulin 
resistance and beta cell proliferation[5,7]. These hormones can also affect transporter expression 
and aid in the preparation of the mother for lactation and continued support of fetal growth[5,7]. 
Lastly, beyond exchanging nutrients, the placenta is responsible for exchanging oxygen 
and carbon-dioxide between the maternal and fetal blood supply. Low oxygen availability can 
affect cell differentiation, placenta structure[8], and can adversely affect fetal growth and 
contribute to disease[9]. Research has indicated that, not only is a healthy and properly 
functioning placenta important for a healthy pregnancy and fetus, but placental defects can affect 
the mother and child long after it has been discarded[10–12]. 
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Human Placental Development  
It is through the placenta that nutrients and other necessary materials are able to reach the 
growing embryo. The placenta is comprised of a variety of trophoblast cells stemming from the 
trophectoderm, the outer layer of the blastocyst. After implantation, cytotrophoblast cells fuse 
together and form the multinucleated syncytium, which invades into maternal decidua [Figure 
1.3a]. Gaps within the syncytium develop and fuse together while the syncytium invades into 
maternal tissue, eroding endometrial blood vessels. This allows the gaps, or lacunae, to fill with 
the maternal blood[13]. Cytotrophoblast begin to expand into the syncytium forming primary 
villi, a cytotrophoblast core with a syncytiotrophoblast outer layer. Shortly after, extraembryonic 
mesenchyme cells invade into the primary villi forming the secondary chorionic villi[13] [Figure 
1.3b ]. Embryonic blood vessels form within the secondary chorionic villi, creating tertiary 
villi[13], which begin to form branches, increasing their surface area. These villi, covered by 
syncytiotrophoblast, are bathed in the maternal blood within the intervillous space [Figure 1.3c], 
regulating the exchange of nutrients and oxygen between the maternal and fetal blood supply. 
The nutrient and oxygen depleted fetal blood enters the intervillous space where the materials are 
passed through the villi into the fetal blood supply and are taken back to the embryo[14]. 
 Figure 1.3. Human placenta formation. (a) At implantation, the syncytium, made of fused 
cytotrophoblast, invades the maternal decidua. (b) Cytotrophoblast cells, followed by 
mesenchyme cells, expand into the syncytium forming secondary villi, structures that will later 
comprise the villous tree.  (c) The villi begin to increase surface area by forming branches that 
will be in contact with maternal blood within the intervillous space. Figure adapted from [15,16]. 
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Disruptions in any part of this precisely regulated process, the development of the villi, the 
branching, reduced blood flow, or transportation misregulation, can result in a variety of diseases 
and adverse pregnancy outcomes. As mentioned previously, nutrients are carried through the 
maternal blood, transported across the barrier comprised of syncytiotrophoblast and transferred 
to fetal blood. When chorionic villi fail to form correctly, or when the maternal blood supply is 
reduced, the availability of nutrients for the fetus is affected. When nutrients are unable to reach 
the fetus properly or efficiently, several problems can arise.  
A common issue, affecting about 5-15% of all pregnancies in the United States and Europe, 
is intrauterine growth restriction (IUGR), when a fetus is growing at a slower than normal rate 
within the womb[4] which may stem from failure of the placenta to deliver the proper amount of 
nutrients to the fetus[4]. On the other hand, some babies are large for their gestational age. This 
is a common outcome of gestational diabetes mellitus, which is associated with 
hypervascularization of the placenta[17]. Hypervascularization may contribute to a larger 
volume of nutrients reaching the placenta, contributing to abnormally large babies. Along with 
effecting fetal size, placenta abnormalities are also a frequent cause of fetal death[18,19]. 
Understanding the etiology of placental diseases is crucial for developing methods to treat, 
diagnose, detect, and prevent them. Using the mouse placenta as a model for human placental 
development has greatly contributed to our understanding about the development and function of 
the placenta.   
Using a Mouse Model to Study Human Placental Development 
In mouse the outer layer of the of the blastocyst is the trophectoderm, the source of 
trophoblast stem cells[15].  These cells proliferate and differentiate, forming several important 
structures: the ectoplacental cone, which later gives rise to the spongiotrophoblast and secondary 
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trophoblast giant cells; the allantois, which forms the umbilical cord and contains fetal blood 
vessels; and the chorion, which will produce syncytiotrophoblast helping to form the 
labyrinth[15,20,21]. At ~e8.5, the chorion and allantois connect, a process known as 
chorioallantoic attachment, beginning the formation of the labyrinth zone[15]. The chorionic 
ectoderm begins to fold onto itself creating finger like protrusions, triggering trophoblast cells to 
fuse, forming syncytiotrophoblast[22]. These syncytiotrophoblast will then form sinusoids, or 
small blood vessels, containing maternal blood. The labyrinth layer continues to mature through 
branching morphogenesis, creating a larger surface area[22]. 
The mouse placenta is a widely used model of the human placenta, though several 
differences exist. Unlike human, mice have a visceral yok sac, which is responsible for materno-
fetal exchange before the placental circulation is established[23]. Rodent placentas are also 
trichorial, containing 3 cell layers separating the maternal and fetal blood, while humans placenta 
are monochorial in the latter half of pregnancy[24]. Another commonly cited difference is that 
trophoblast invasion, the process by which trophoblast invade into the decidua to anchor the 
placenta and remodel maternal vasculature, is deeper in human placental development than in 
mice[24]. 
However, many important similarities between the human and mouse placenta have also 
been noted. For instance, both have a disc-shaped hemochorial placenta, tasked with regulating 
the exchange of nutrients and gases to and from the fetus. Other animals have different types of 
placenta such as epitheliochorial (horses, pigs and ruminants) or endotheliochorial (carnivores), 
which differ from hemochorial in the number of cell layers between maternal and fetal 
blood[25]. Many structural similarities also exists between human and mouse 
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placentation[15,21].  Similar to the villous tree in human, the labyrinth layer in mouse is the site 
of nutrient and gas exchange between the maternal and fetal blood supply.  
Humans and mice also share several orthologous genes. For example, both mouse and 
human insulin growth factor-2 is associated with fetal growth and nutrient delivery[26,27]. 
Decreased expression of Esx1 has also been associated with fetal growth retardation in both 
species[28,29]. Several other studies have shown that errors in gene regulation in the placenta 
lead to inefficient labyrinth development and transportation between the mother and fetus, 
resulting in embryonic lethality. Mouse placentas lacking Gcm1 fail to form the labyrinth layer 
and embryos die in utero[30]. Human placentas lacking Gcm1 show alterations in trophoblast 
differentiation, specifically syncytialization[31]. On the other hand, overexpression of sFLT1 in 
mice mirror human preeclampsia symptoms[32]. Other papers have reviewed several genes 
whose knockouts have devastating effects during placental development[20,33,34], indicating 
that the precise spatio-temporal expression of genes is required for proper placental development 
in both mouse and human.  
The mouse model is also useful due to its large litter size and short gestation period, 
making it possible to collect enough tissue early in the developmental process for 
experimentation. For all of these reasons, there has been a large amount of research done with 
mouse which prove it to be an invaluable tool with many knockout models and established 
protocols for genetic manipulation[35].  
Regulation of Gene Transcription 
 Genes can be regulated at the transcriptional, post-transcriptional, translational, or the 
post-translational level. The genes that are not required for cell survival or housekeeping 
functions may be kept in an ‘off’ state within heterochromatin which is tightly wrapped around 
histones in a condensed manner [Figure 1.4a]. The chromatin is modified to and from this state 
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by modifications to the amino terminal tails of the histones. These histones can be modified via 
many mechanisms, however the most common are methylation and acetylation. Methylation by 
histone methyltransferases generally signals gene silencing and DNA condensation. However, 
acetylation by histone acetyltransferases coincides with active genomic regions and the open, or 
opening, of the chromatin[36]. In order for a gene to be transcribed, it is necessary for it to be in 
an accessible configuration[37].  Once the DNA is accessible, it must be bound by the 
appropriate, activating proteins to initiate transcription. While some of these proteins, or 
transcription factors, bind to promote transcription, others repress it[38] [Figure 1.4b]. 
Identifying the transcription factor and the region it binds are both important aspects of gene 
transcription. Transcription factors bind to the DNA at specific, short DNA sequences, known as 
motifs. Motifs are located in regulatory elements located just before the start of a gene 
(promoter), or at regulatory elements which can be upstream, downstream, or within intronic 
regions of a gene. These regulatory elements are capable of altering DNA structure to bring 
enhancer elements close enough to interact with promoter elements. Activators generally bind 
DNA to increase transcription of a gene, while a repressor binds to decrease or prevent 
transcription[39] [Figure 1.4c]. 
After a gene is transcribed, it is subjected to post-transcriptional modifications which 
may include capping at the 5’ end, polyadenylation, and intron splicing. Next, the mRNA is 
translated to an amino acid chain via a ribosome in the cytoplasm, after which it can be subjected 
to various posttranslational modifications, such as the acetylation or methylation of histones as 
mentioned previously. Proteins are also subjected to several other modifications including 
phosphorylation, ubiquitination, and glycosylation which can contribute to protein folding, 
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stability, localization, or activity[40]. Our work focuses on the first step of regulation, at the 
transcriptional level. 
Figure 1.4. Gene regulation summary. (a) Inactive chromatin is wrapped around nucleosomes 
marked by H3k27me3. (b) Active promoters are generally marked by H3k27ac and H3k4me3 
and must be bound by the appropriate activators in order to promote transcription. Promoters can 
be repressed or poised if activators are absent or if repressors bind to the promoter, preventing 
activator binding. Poised promoters are marked by H3k27me3 and H3k4me3. (c) Enhancers 
bound by the appropriate activators can act on promoters by looping, bringing the enhancer in 
close proximity to the promoter to enhancer transcription. Enhancers will not be active if they 
lack the appropriate activators. Figure adapted from [41]. 
Experimental Methods to Understand Gene Transcriptional Regulation 
 
To understand the regulation of a gene, it is necessary to identify regulatory regions and the 


















for this purpose. However, these techniques generally focus on a single, or small group of genes. 
With the advent of next generation sequencing, several assays have become high throughput and 
offer information about the whole genome. Many of these assays have been used to gain insight 
into placental development. One such assay, DNAse-seq[42] was designed to identify areas of 
the genome that are hypersensitive to DNase I cutting[42] and are therefore accessible regions. 
Other methods, including FAIRE-seq[43] and ATAC-seq[44], have been developed to obtain 
similar information more efficiently. ATAC-seq is a quicker protocol, requiring less starting 
material than the other two protocols. ATAC-seq has quickly become a popular method and has 
been used to further our understanding of the placenta through the identification of complexes 
which maintain open chromatin[45]. Also, by mapping how chromatin accessibility changes 
across differentiation, researchers have found key genes that gain accessibility as trophoblasts 
differentiate and have found that inaccessibility is not the only explanation for downregulation, 
but transcription factors may also repress trophoblast stem cell genes[46]. Therefore, simply 
identifying accessible regions does not tell us if the region is active, repressed, or poised[46–48], 
though many researchers commonly associate accessibility with transcriptional activity.  
A popular method to properly annotate these genomic regions is chromatin 
immunoprecipitation with sequencing (ChIP-seq) for histone modifications. Using an antibody 
against a specific histone marker will identify where in the genome a modification is, which 
allows us to infer the role of the nearby DNA. Some marks correspond to active or repressed 
regions of the genome such as H3k27ac[49,50], H3k27me3, and H3k9me2[49]. Other marks are 
more associated with a type of regulatory region. For example, high activity of H3k4me1 and 
low activity of H3k4me3 can be found at enhancers, while the reverse pattern marks 
promoters[51]. ChIP-seq can also be used to identify where transcriptional machinery is binding, 
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like RNA-PolII[52], or to identify the binding of other specific transcription factors. ChIP-seq 
experiments have provided insight in the mechanisms of proper placental development, 
identifying target genes and regulators that control important aspects of placental development 
such as trophoblast differentiation[46,53] or branching[54]. ChIP has also been used to further 
our understanding of how normal placental development is affected by disease. For example, 
H3k27ac ChIP-seq was performed in placentas from healthy pregnancies and those complicated 
by fetal growth restriction. By comparing the acetylated regions, the researchers found that 
several genes associated with hyperacetylated sites were involved in the HIF-1-alpha 
transcription factor network and hypoacetylated genes were related to growth hormone receptor 
signaling[55]. Identifying where regulation is altered in diseased placentas helps to provide 
potential targets for future therapies. Other studies have focused on identifying tissue, species, or 
timepoint-specific regulatory regions[56–58], though such studies require more data 
accumulation for comparison. Also, since the landscape changes throughout development, it is 
critical that we produce data to aid in annotating the placenta genome at several timepoints. Such 
information will help us to identify novel regulatory elements that may be necessary for a proper 
transcription of a gene in a particular context – such as a specific tissue or disease.  
ChIP has been an invaluable resource for studying the placenta and the protocol is still 
improving. Several other experiments, such as ChIP-exo, have been published that improve on 
the original protocol, resulting in less noise and higher binding site resolution[59]. ChIP has also 
been combined with mass spectrometry in order to identify protein-protein interactions[60]. 
Knowing where these transcription factors, or histone modifications binds allows us to identify 
regulators of transcription or potential sites of transcription, while RNA-seq[61] allows us to 
measure the amount of transcription taking place genome-wide. 
12 
 RNA-seq has been pivotal for understanding gene expression patterns during placental 
development, and in placental disorders. Several studies have investigated genes misregulated in 
diseased placentas, providing researchers with a better understanding of potential causes or 
targets for potential therapies. One such study identified genes misregulated in the IUGR 
placenta compared to normal controls, some of which are involved in inflammation and 
immunity[62]. Other researchers have used RNA-seq to compare several diseased placenta, or 
those related to adverse outcomes such as preeclampsia, gestational diabetes, and small or large-
for-gestational-age newborns. Gene expression was analyzed for all groups and compared 
between all groups, as well as the normal placenta[63]. This revealed several surprising 
similarities between placental complications, perhaps indicating a common transcriptomic 
response to different placental malfunctions[63].  RNA-seq has also been used to characterize 
general sex-differences within the placental genome[64], as well as specific mechanisms such as 
trophoblast differentiation. One research group performed RNA-seq on BeWo cells with and 
without forskolin, representing syncytiotrophoblast and cytotrophoblast, as well as placental cell 
cultures (cytotrophoblast and syncytiotrophoblast). By comparing the differentially expressed 
genes from both models, they found several candidates for syncytialization[65], which is 
important due to the relationship between syncytialization and placental disease[66]. 
Understanding the subtypes of trophoblast and the differences in their gene expression has only 
improved with the use of single-cell RNA-seq[67], allowing the comparison of several cells 
within the placenta simultaneously[67].  However, to better understand the cause of the 
expression changes based on disease or sex, RNA-seq must be combined with other methods, 
such as ATAC-seq and ChIP-seq as mentioned before. Several of the studies mentioned fail to 
incorporate information to identify the cause of the transcriptomic misregulation, an important 
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aspect of understanding function, development or disease. Therefore, it is crucial to develop 
methods and generate data allowing us to integrate several types of omics data to get the most 
complete view of genetic regulation within the placenta.  
Computational Methods to Understand Gene Transcriptional Regulation 
Several next generation sequencing techniques rely on similar pipelines for analysis. 
Over time, new methods, analysis, and interpretations are published, several of which provide 
only minor differences – a more streamlined approach, a faster runtime, a more intuitive output – 
leading researchers to have to wade through the vast amount of information to find the best 
analysis for their particular data. However, there is generally a common pipeline that can be used 
and several methods rely on the same basic steps.  
First, after obtaining a fastq file, the quality of the reads is checked, commonly by the 
FASTQC[68] software. FASTQC is a quick method that allows the user to identify basepairs of 
poor quality, adapters, and high or low GC content. If necessary, reads can then be trimmed to 
remove low quality basepairs adapters, or perform other read filtering using one of several 
methods such as Trimmomatic[69], bbduck (https://sourceforge.net/projects/bbmap/), or Trim 
Galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Rechecking the 
quality after trimming assures the user that the proper basepairs or adapters were trimmed. Low 
quality reads and basepairs can lead to low alignment and adversely affect follow up analysis. 
Generally, after quality control, reads can then be aligned to the reference genome. Several 
aligners are available, although the choice of aligner is dependent upon the data. For example, 
bowtie[70] and bwa[71] are popular aligners for data such as ChIP-seq and ATAC-seq which can 
be aligned directly to the genome. However, Hisat2[72] or STAR[73] are more commonly used 
for RNA-seq data, since these programs are created to be splice aware and can align reads to 
exon regardless of the interrupting introns. These aligners rely on a reference genome. When no 
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reference genome is present, or is of poor quality, de novo assembly is required and can be 
accomplished via several different programs such as Trinity[74], transABySS[75] or Oases[76]. 
These programs use de Bruijn graphs to parse reads into k-mers, identify overlapping k-mers and 
reassemble them into longer sequences[77].  
Generally, after alignment, analysis methods tend to branch off. Peak-calling is a 
common next step to identify accessible regions identified by pile-up of ATAC-seq reads, or to 
identify the location of transcription factor binding or histone modification activity by pile-up of 
ChIP-seq reads. Several peak calling methods have been proposed including MACS2[78], 
GLITR[79], Genrich (available at https://github.com/jsh58/Genrich), and Homer[80]. Such peak 
callers differ in their sensitivity (calling true peaks), and their specificity (avoiding false 
ones)[81,82]. Peaks also vary widely depending on the experiment, and can be narrow and sharp, 
or broad and wide; they can cover large amounts of the genome or be sparse. Therefore, peak 
callers must be able to adapt their criteria of what a “peak” is, and the user must be able to 
choose appropriate options and criteria for accurate peak calling, or be able to filter noise from 
peaks in a downstream analysis. It is important to take into account the data when choosing a 
peak caller to get the most accurate results. 
RNA-seq downstream analysis doesn’t rely on peak-calling but instead includes 
transcript counting in order to quantify expression within the genome. Generally, these counts 
are necessary to compare transcript expression between multiple timepoints or treatments, to see 
how the expression changes and what genes are affected by the changes, in order to gain 
biological insight of their role. Common tools for such an analysis include edgeR[83], 
DEseq2[84], TSPM[85], and SAMseq[86]. While these and several other methods have been 
tested extensively on various datasets, their ability to identify differentially expressed genes is 
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dependent upon the underlying gene expression distribution, outliers, and variance between 
replicates[87].  
The same principle has been applied to experiments outside of RNA-seq in order to 
identify accessibility differences or peak signal differences within the genome, which produces a 
unique set of challenges: 1) peaks can be more dispersed throughout the genome, unlike 
transcripts that are limited to exons; 2) such experiments generally have substantial amounts of 
noise making true signal more difficult to detect; and 3) the properties of peaks vary widely (as 
discussed above with peak calling)[88].  
However, several other analysis options exist. After alignment ATAC-seq can be 
analyzed by NucleoATAC[89] in order to identify the location of nucleosomes and nucleosome 
free regions. Accessible regions are typically associated with the nearest genes and positively 
correlated with their expression[90–92]. However, this correlation is not perfect and several 
papers have cited accessibility at genes with low expression[47,48,93]. Therefore, more 
investigation is needed to fully understand how accessibility relates to gene expression and its 
role in transcriptional regulation. ChromHMM[94] can be used to combine several ChIP-seq 
experiments in order to identify similar patterns throughout the genome and group them[95].  
Such an analysis requires several datasets and biological interpretation can be difficult due to the 
various definitions of peaks. For example, H3k4me3 is typically found at active promoters but 
does not always signal activation[96]. ChromHMM states are also affected by the ChIP signals 
used as input, such that one promoter may be associated with a variety of patterns due to the 
variability of width and signal of different datasets. Lastly, techniques like weighted gene 
coexpression network analysis (WGCNA) can be used with RNA-seq data in order to identify 
modules of genes that may work together, signified by shared expression patterns across multiple 
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samples[97]. Such methods require large amounts of data and samples, which may be difficult to 
acquire. And although genes may follow a similar pattern, it is not necessary that they work 
together.  Once a set of interesting regions/genes has been defined, network analysis, ontology 
enrichment, pathway enrichment or several other analyses can be performed to gain biological 
insights into the function and regulation of the genes. 
Although the tools described are readily available, the particular choice of aligner, peak-
caller, or transcript counter, must be made with care for a particular dataset to account for biases 
from particular datasets and make accurate conclusions from the data. To elucidate accurate 
biological insight from such data, downstream analysis is also critical. The filtering criteria, 
statistical test to test differences in datasets, clustering methods, etc. must be chosen by the 
researcher. There are also several ways to interpret the data, and many options for downstream 
analysis, all dependent upon the biological question being answered. Choosing and running a 
tool is only a small part of the analysis necessary for understanding the given data and drawing 
accurate and thorough biological conclusions.  
Summary 
Next generation sequencing has been instrumental in advancing our knowledge about the 
gene regulatory networks guiding the development and function of the placenta and contributing 
to disease. Each method provides a small picture of what is going on inside a cell, however, a 
full picture can only be obtained through the integration of multiple experiments and datasets. 
We propose to use multiple methods to elucidate the molecular mechanisms regulating gene 
transcription during a critical stage of murine placental development.  
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First, we analyzed the genome-wide chromatin landscape of the midgestation mouse 
placenta. We combined genome-wide accessibility data using ATAC-seq, and gene-expression 
from RNA-seq[93]. In order to better understand how accessibility relates to gene expression, we 
correlated the accessibility at a gene’s promoter with its expression. Generally, the amount of 
accessibility at a gene’s promoter and the gene’s expression are positively correlated[90–92]. 
However, we delved deeper into this relationship with a special focus on genes deviating from 
this pattern. By analyzing genes with high accessibility and medium-low expression we 
identified a group of actively repressed neuronal genes, enriched for a repressive histone mark at 
the promoter. Unexpectedly, we also found a group of genes that showed high expression but 
had low promoter accessibility that were largely placenta-specific [Figure 1.5]. 
Figure 1.5. Summary of Project I. ATAC-seq and RNA-seq data were integrated and promoters 
were divided into one of 5 groups based on their promoter accessibility and gene expression. 
Potential actively repressed genes had high accessibility with medium-low expression while 





ATAC RNA GroupATAC-seq data
RNA- seq data
Brain-specific genes
HA-ME : Repressed genes
Placenta-specific genes
MA-HE : Active genes
Step 1: Step 2:
Step 3:
18 
Next, to more comprehensively annotate the genomic landscape in the midgestation 
placenta, and identify the activity and location of regulatory elements, we generated data for 
several histone modifications. We combined ChIP-seq data for active (H3k27ac, H3k4me3, 
H3k4me1) and repressive (H3k27me3) histone modifications [Figure 1.6]. By observing 
different patterns of the mark throughout the genome, we identified active promoters and 
enhancers and their putative gene targets. We identified several bivalent genes with important 
roles in early placental development as well as novel transcription factors with enriched binding 
sites in active enhancers with predicted roles in placental blood vessel development. 
Lastly, we incorporated H3k27ac ChIP-seq data (active enhancer data) and RNA-seq data 
in order to identify transcription factors important for placenta function during midgestation 
development.  We found that the transcription factor, PLAGL1, was upregulated and had more 
predicted binding sites within e9.5-specific enhancers, than enhancers identified at an earlier 
time point. This led us to investigate the potential role of PLAGL1 in both the mouse and human 
placenta. We found PLAGL1 mouse enhancers to be associated with genes associated with blood 
vessel development. Using RNA-scope, we found that it was expressed in fetal endothelial cells 
and within the allantois. We also found Plagl1 to be differentially expressed between normal 
placentas and the placentas of a gestational diabetes mouse model, but only in males.  In human 
trophoblast cells, we knocked down PLAGL1 and found a plethora of vasculature development 
genes misregulated. A tube-assay performed on the knockdown cells revealed that decreased 
PLAGL1 expression has a negative effect on endothelial-like tube formation by decreasing cord 
19 
formation, an important step in overall tube development. This evidence shows PLAGL1 to be 
an interesting candidate in the etiology of placental disease [Figure 1.7]. 
Figure 1.6. Summary of Project II. ChIP-seq data was generated and analyzed for several histone 























Overall, combining experimental and computational techniques allowed us to (1) develop 
new methods for understanding and analyzing ATAC-seq data, (2) annotate the enhancers, 
repressors, and promoters across the placental genome, and (3) identify a novel transcription 
factor candidate for blood vessel development. This work lays the foundation for many future 
projects that will continue to increase our understanding of the placenta and its associated 
diseases and contribute to the development of cures, treatments, and preventative measures.  
Figure 1.7. Summary of Project III. RNA-seq and ChIP-seq enhancer data was integrated and 
Plagl1 was found to be upregulated at e9.5 and have enriched binding sites in e9.5-specific 
enhancers. Follow up analysis found Plagl1 to be expressed in mouse placental labyrinth and 
differentially expressed in the placenta of mice modeling gestational diabetes compared to 
control. We found that knocking down PLAGL1 in human trophoblast cells affected the cells 
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Abstract 
The assay for transposase-accessible chromatin (ATAC-seq) is a powerful method to 
examine chromatin accessibility. While many studies have reported a positive correlation 
between gene expression and promoter accessibility, few have investigated the genes that deviate 
from this trend. In this study, we aimed to understand the relationship between gene expression 
and promoter accessibility in multiple cell types while also identifying gene regulatory networks 
in the placenta, an understudied organ that is critical for a successful pregnancy. 
We started by assaying the open chromatin landscape in the mid-gestation placenta, when 
the fetal vasculature has started developing. After incorporating transcriptomic data generated in 
the placenta at the same time point, we grouped genes based on their expression levels and 
ATAC-seq promoter coverage. We found that the genes with the strongest correlation (high 
expression and high coverage) are likely involved in housekeeping functions, whereas tissue-
specific genes were highly expressed and had only medium–low coverage. We also predicted 
that genes with medium–low expression and high promoter coverage were actively repressed. 
Within this group, we extracted a protein–protein interaction network enriched for neuronal 
functions, likely preventing the cells from adopting a neuronal fate. We further confirmed that a 
repressive histone mark is bound to the promoters of genes in this network. Finally, we ran our 
pipeline using ATAC-seq and RNA-seq data generated in ten additional cell types. We again 
found that genes with the strongest correlation are enriched for housekeeping functions and that 
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genes with medium–low promoter coverage and high expression are more likely to be tissue-
specific. These results demonstrate that only two data types, both of which require relatively low 
starting material to generate and are becoming more commonly available, can be integrated to 
understand multiple aspects of gene regulation. 
Within the placenta, we identified an active placenta-specific gene network as well as a 
repressed neuronal network. Beyond the placenta, we demonstrate that ATAC-seq data and 
RNA-seq data can be integrated to identify tissue-specific genes and actively repressed gene 
networks in multiple cell types. 
Introduction 
The placenta is a transient organ, critical for fetal survival within the uterine 
environment. It is the only physical connection between the mother and fetus, supplying the fetus 
with the nutrients, oxygen, and hormones necessary for proper development [1, 2]. Rodents and 
primates have a hemochorial placenta [3], in which maternal blood is in direct contact with the 
chorion in the intervillous space. To allow for a more efficient exchange of oxygen and nutrients 
between maternal and fetal blood, the fetal placenta undergoes branching morphogenesis, which 
increases its surface area and allows a complex vascular network to develop [4]. In mice, defects 
in branching morphogenesis or vasculature development, sometimes associated with abnormal 
gene expression, commonly lead to embryonic lethality midway through gestation [1]. For 
example, simultaneous deletion of the Hey1 and Hey2 transcription factors results in embryonic 
lethality at approximately embryonic day (e) 9.5, due to decreased vascular remodeling [5]. As 
another example, EpCAM-null mice show evidence of insufficient vasculogenesis in the fetal 
placenta by e9.5, which contributes to embryonic lethality by e12.5 [6]. 
In addition to gene knockout studies, transcriptome studies have been carried out to 
identify genes that are expressed in the placenta at e9.5, as well as at other time points [7,8,9]. 
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However, transcriptome studies alone cannot provide insight into tissue-specific gene networks 
when they are carried out in a single tissue, and also cannot provide information on genes that 
are actively repressed in a particular context. To better understand these aspects of gene 
regulation, chromatin immunoprecipitation followed by sequencing (ChIP-seq) data for several 
histone modifications, such as H3K4me3, H3K27ac [10], and H3K27me3 has been integrated 
with RNA-seq data across multiple tissues [11]. However, generating multiple ChIP-seq datasets 
with sufficient biological replicates and controls is costly and typically requires a large amount 
of starting material. 
The assay for transposase-accessible chromatin using sequencing (ATAC-seq) is a 
promising recent technique that can be used to address some of these issues, requiring a 
relatively low amount of starting material [12]. Additionally, since ATAC-seq data are 
associated with nucleosome depletion, it can be used to identify genomic regions associated with 
gene activation or gene repression. Several studies that have integrated ATAC-seq and RNA-seq 
data reported a positive correlation between the ATAC-seq signal at a gene’s promoter and its 
expression [13,14,15]. Despite this correlation, many studies find that changes in the chromatin 
landscape are not always associated with expected changes in transcription [16,17,18]. Still, a 
thorough investigation into this correlation, and the genes that seem to deviate from it, is lacking. 
In order to better understand gene regulation in the placenta, as well as the relationship 
between accessibility at a gene promoter and gene expression, we generated ATAC-seq data in 
the mouse placenta and integrated it with RNA-seq data generated in the same context [9]. We 
then defined gene groups based on the level of ATAC-seq signal at gene promoters and the 
corresponding gene expression level, according to RNA-seq. In addition to identifying genes 
with a strong positive correlation, we also identified genes with medium–low expression and 
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high ATAC-seq promoter coverage, and genes with high expression and medium–low ATAC-
seq promoter coverage. Investigating these gene groups further led us to identify a neuronal 
network that we predict is actively repressed in the placenta, as well as a set of placenta-specific 
genes and subnetworks that are associated with specific functions of the placenta. Finally, we 
analyzed previously published ATAC-seq and RNA-seq datasets generated in 10 additional 
contexts using our pipeline. We were consistently able to identify tissue-specific genes, as well 
as actively repressed gene networks. Therefore, in addition to identifying novel regulatory 
mechanisms in the placenta, we also better defined the relationship between promoter 
accessibility and gene expression and demonstrated how to integrate ATAC-seq and RNA-seq to 
identify tissue-specific genes. 
Methods 
ATAC-seq library preparation and sequencing 
ATAC-seq was performed as previously described [72]. Briefly, two e9.5 placentas were 
microdissected from timed-pregnant CD-1 mice (Charles Rivers Labs) for each biological 
replicate (3 replicates in total). After tissue homogenization and cell lysis, we followed the 
transposition and purification steps as described previously [72]. We amplified the purified DNA 
for 12 cycles following conditions specified in [72] using adapters from the Nextera index kit 
(Illumina) (Appendix B: Table 2.3). PCR purification was performed using AMpure XP beads 
(Beckman Coulter) in order to remove large fragments and remaining primers. Library quality 
was assessed using the Bioanalyzer High Sensitivity DNA Analysis kit (Agilent) to check for 
proper periodicity, and the DNA concentrations were estimated using the Qubit and Bioanalyzer 
Appendix A: Figure 2.6a). Libraries were sequenced by Elim Biopharmaceuticals, Inc. using the 
Illumina HiSeq2500 Rapid run platform with 50 bp paired-end sequencing. Before filtering, 
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there was an average of about 82 million reads (73–93 million), and after filtering there was an 
average of about 18.8 million reads (16–20 million) (Appendix B: Table 2.4). 
Mouse data curation 
Mouse data were compiled from previous studies published until Dec. 2017. Mouse data 
were considered for analysis if they had at least two biological replicates and had RNA-seq data 
available in the same cell line and tissue. Only paired-end ATAC-seq data were considered. 
ATAC-seq data processing 
Additional ATAC-seq data used for analysis were obtained from the Gene Expression 
Omnibus (GEO) (Appendix B: Table 2.5). For all samples, read quality was assessed using 
FastQC [73]. Trimmomatic [74] (default settings) was used to remove adapters and low-quality 
base pairs and reads identified by FastQC. Reads for each mouse sample were aligned to the 
mouse genome (mm9) and reads for human samples were aligned to the human genome (hg19), 
using Bowtie2 [75] (v.2.3.1; very-sensitive, maxins 2000, no-discordant). Each sample had high 
overall alignment rates, with an average alignment of 93% for all mouse samples (Appendix B: 
Table 2.5). After alignment, we removed reads with a mapping quality lower than 20, with more 
than two mismatches, and those mapping to the mitochondrial genome. We also removed 
duplicate reads using Picard tools v.2.2.4 (http://broadinstitute.github.io/picard) and offset the 
reads to account for the transposon dimer [76]. Final read counts for all mouse datasets ranged 
from 4 to 53 million reads (Appendix B: Table 2.4). 
Fragments that were less than the length of one nucleosome (140 bp—previously 
described as subnucleosome sized [77]) were considered as aligning to nucleosome-free, or 
“open regions” of the genome. After confirming replicates were highly correlated with each 
other, reads aligning to open regions were combined for all replicates. We then determined the 
maximum number of overlapping reads (scaled by the library size) in the promoter of each gene. 
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Gene promoters were defined as 500 bp up or downstream of a transcription start site (TSS), and 
TSS coordinates were obtained from the UCSC Genome Browser knownGene (mm9) [78] table. 
For genes with multiple isoforms, the isoform promoter with the maximum number of 
overlapping reads was retained for further analysis. 
RNA-seq data processing 
RNA-seq datasets were downloaded from GEO (Appendix B: Table 2.6). FastQC was 
used to check the quality of reads and presence of adapters, and Trimmomatic (default settings) 
was used to remove adapters and low-quality reads and base pairs. Reads for mouse samples 
were then aligned to the mouse genome (mm9), and reads for the human samples were aligned to 
the human genome (hg19), using HISAT2 [79] (v.1.0.4; default parameters). Reads aligning to 
the mitochondrial genome were removed. Transcript abundance was calculated using htseq-
count from the HTseq [80] software package. Transcripts per million (TPM) values were 
calculated as previously described [81], by normalizing the transcript count by the gene length 
followed by the library size. Values were then averaged across biological replicates for each 
gene. 
Integration of ATAC-seq and RNA-seq 
Genes were defined as highly accessible (HA) if the maximum number of overlapping 
ATAC-seq reads within their promoter (accessibility) was higher than the 70th percentile of the 
data, and were defined as having medium–low accessibility (MA) if the coverage was below the 
50th percentile. Genes were defined as highly expressed (HE) if their TPM was higher than the 
70th percentile of the data, and were defined as having medium–low expression (ME) if the TPM 
was below the 50th percentile. Each gene was then evaluated to determine whether it could be 
assigned to one of four groups: MA–ME (medium–low accessibility and expression), HA–HE 
(high accessibility and expression), HA–ME (high accessibility and medium–low expression), or 
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MA–HE (medium–low accessibility and high expression) based on its accessibility and 
expression values. Genes that did not fall into one of the four described categories were not used 
in the analysis, in order to maintain stringent gene groups. 
Gene ontology and network analysis 
Gene ontology enrichment analysis was performed using the Genomic Regions 
Enrichment of Annotations Tool [26] (GREAT) using the GO biological process ontology. 
Terms were considered significantly enriched if they had at least 5 genes from the input set, a 
fold of at least 2, and a false discovery rate (FDR) less than 0.05 according to the hypergeometric 
statistic [26]. For all analyses, the top 5 terms (ranked by FDR) are displayed unless otherwise 
indicated. 
Protein–protein interaction networks were built using the STRING database [43] (v.10.5). 
The STRING database provides protein–protein associations determined through experimental 
data, text-mining, and other databases. The database includes direct and indirect interactions. In a 
STRING network analysis, a line is drawn between two genes if they are predicted to have an 
interaction with a certain confidence. We used a confidence threshold of 0.70 and the default 
parameters in order to build protein–protein interaction networks. STRING networks were 
downloaded and hub nodes were identified using Cytoscape [53] (v.3.5.1) based on the number 
of connections between nodes. Clustering of subnetworks was performed using the Cytoscape 
GLay plugin [52] (default parameters). 
Motif enrichment analysis 
The library of position weight matrices used to score binding sites in promoters was 
obtained by curating data from multiple resources described in [35]. We removed motifs with a 
low information content (< 10) and those corresponding to genes that had low expression in e9.5 
placenta (TPM ≤ 5), leaving 681 motifs. Binding sites were predicted using the PRISM 
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phylofootprint approach [35]. This method has been shown to predict transcription factor binding 
sites with high accuracy, using an excess conservation metric that measures the likelihood for a 
binding site to be conserved in a particular region [35]. Binding sites that are conserved more 
strongly than surrounding sequences are favored [35]. Predictions were required to have a match 
threshold ≥ 0.8 (80% similarity), a significance of ≤ 0.05 (when compared to shuffled motifs 
predicted in similar sequences), and had to be conserved in the human genome (hg19). 
Similar motifs in the library were identified as previously described [82, 83], using a 
similarity threshold of 0.8. The motif with the highest number of predicted binding sites was kept 
for further analysis (Appendix B: Table 2.1). For each transcription factor motif, a fold was 
calculated as the ratio of the proportion of promoters containing the motif in the target gene set 
to the proportion of promoters containing the motif in a background set of genes. A transcription 
factor motif was considered to be enriched in the gene set if it had a fold ≥ 2 and a q value ≤ 0.05. 
Significance was determined using the Bonferroni-corrected hypergeometric p-value. 
Tissue-specific gene enrichment analysis 
We used TissueEnrich [48] to carry out tissue-specific gene enrichment analysis, using 
all of the tissue-specific genes from the mouse ENCODE dataset and default parameters. The 
enrichment was calculated by using the hypergeometric test. Tissue-specific gene sets were 
considered enriched if they had an adjusted p-value ≤ 0.01. 
H3K27me3 chromatin immunoprecipitation (ChIP) 
Placentas were microdissected from e9.5 timed-pregnant CD-1 mice (Charles Rivers 
Labs). Three placentas were combined per biological replicate, and three biological replicates 
were carried out. Chromatin isolation was carried out as previously described in [84] except that 
the final nuclear lysis was performed in 0.5% of TritonX-100, 1 mM EDTA, 10 mM Tris–Cl, pH 
8.1 and the chromatin was sheared using the Bioruptor Pico for a total of 6 cycles (30 s 
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on/30soff). The H3K27me3 ChIP was carried out with 10ug of chromatin and 4ug of H3K27me3 
antibody (Millipore 17-622, lot:3070997) as per manufacturer’s recommendation following the 
ChIP protocol as previously described in [84]. We quantified the level of H3K27me3 activity 
with Real-Time qPCR. Gapdh and sheared genomic DNA (input DNA) were used for 
normalization and enrichment calculation, using the ∆∆Ct method. Primer sequences and 
efficiency values, calculated after testing 1:4 dilutions of input DNA, are listed in Appendix B: 
Table 2.7. 
Randomization analysis 
Randomization analysis was performed to determine the significance of specific ontology 
terms within subnetworks or gene groups. We generated 10,000 gene sets that matched the size 
of the group or subnetwork of interest. For each of the random sets, we obtained the FDR of a 
specific term using GREAT. The p-value is equivalent to the number of random sets that have a 
lower FDR than our original term, divided by 10,000. 
Comparison of gene groups between tissues 
The pairwise comparison of genes in each group for all tissues (Appendix A: Figure 2.11) 
was calculated by comparing the genes of the same group between each pair of tissues. The 
Mann–Whitney U test was used to check whether the set of overlap counts was significantly 
different between groups. 
Recon and nuScore analysis 
For each gene, we created a fasta file for the region 500 bp upstream of the TSS. These 
sequences were used as input to the Recon (http://wwwmgs.bionet.nsc.ru/mgs/programs/recon/) 
or the nuScore (http://compbio.med.harvard.edu/nuScore/) web-tools [50, 51], to obtain 
nucleosome position scores or deformation energy, respectively. NuScore was run using the 2cv5 
human template and default parameters. Recon was also run with the default parameters. 
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Nucleosome position scores for each position were averaged across all sequences within a 
particular group. Similar averaging was also done on the deformation energy across all 
sequences within a group. To determine whether the mean nucleosome position score was 
significantly different between the tested groups, we used the Mann–Whitney U test. 
Results 
Identifying accessible regions in the mid-gestation mouse placenta 
To define the chromatin landscape in mouse placenta at e9.5, we carried out ATAC-seq 
for three biological replicates, as described in the methods. Because ATAC-seq is infrequently 
carried out in whole tissue, we first assessed data quality. The fragment length distributions 
showed the expected periodicity before and after sequencing, with an abundance of fragments 
falling within nucleosome-free regions [≤ 140 base pairs (bp)] (Fig. 2.1a; Appendix A: Figure 
2.6a–c). We then aligned the reads to the mouse genome and calculated the coverage in gene 
promoters, defined as 500 bp surrounding the transcription start site (TSS). We found a high 
correlation between biological replicates [R2 = 0.99 (Pearson)] (Fig. 2.1b; Appendix A: Figure 
2.6d, e) and therefore combined reads across replicates for further analysis. 
As expected, we observed a pileup of ATAC-seq reads (a peak) in the promoters of genes 
that are expressed in the placenta (Fig. 2.1c). A peak was observed in the promoters of many 
housekeeping genes, including Psmd4, Rpl37, and Eif3f, [19] as well as in the promoters of 
genes with known regulatory roles in multiple tissues including the placenta, such as Arnt [20], 
Hif1a [21], and Setd2 [22]. Finally, we found that in general, there is a strong ATAC-seq signal 
centered at gene TSSs (Fig. 2.1d). Together, these data demonstrate a high signal-to-noise ratio 





Figure 2.1. ATAC-seq analysis of e9.5 mouse placenta. a Distribution of ATAC-seq data 
fragment lengths from a representative sample (biological replicate 1). Small fragments 
correspond to open chromatin while peaks at larger fragment sizes represent fragments that span 
one or more nucleosomes. b Scatter plot representing promoter accessibility for each gene in 
replicate 1 plotted against the promoter accessibility for the corresponding gene in replicate 2. 
Biological replicates show a strong correlation, indicated in the red box (Pearson Correlation 
Coefficient). c Representative genes with a pileup of ATAC-seq reads in the promoter 
region. d Heatmap (total number of reads at the start site normalized by library size) and density 
plot of ATAC-seq fragments showing enrichment at gene TSSs (plot includes all knownGenes 
from the UCSC genome browser) 
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ATAC-seq signal at promoters is correlated with gene expression 
Previous studies have reported a significant correlation between gene expression and the 
ATAC-seq signal at a gene’s promoter (the promoter accessibility) [13,14,15]. Therefore, we 
calculated the correlation of promoter accessibility with gene expression. Gene expression was 
measured using transcripts per million (TPM), calculated from previously published e9.5 
placenta RNA-seq data [9]. In agreement with other studies, we found a strong correlation 
between accessibility and expression [R2 = 0.705 (Spearman); p value < 2.2e−16] (Fig. 2.2a). It is 
likely that a higher correlation is typically not observed because accessible regions are not 
always associated with gene activity. They can also be associated with gene repression or genes 
that are poised to become active [23,24,25]. Although some aspects of this correlation have been 
investigated, the majority of studies have not fully explored the relationship between ATAC-seq 
and RNA-seq data, especially with respect to genes that have low accessibility and a high level 
of expression. Therefore, to further understand the relationship between ATAC-seq and RNA-
seq, we divided genes into groups based on their level of expression and promoter accessibility 
(see “Methods”). We found that the majority of genes (8237) had medium–low accessibility and 
medium–low expression (MA–ME), and the second largest group (3527 genes) had high 
accessibility and high expression (HA–HE) (Fig. 2.2b). To determine the biological functions 
associated with these groups, we carried out a functional enrichment analysis using the Genomic 
Regions Enrichment of Annotation Tool (GREAT) [26]. As expected, we found clear 
distinctions between the biological processes enriched in each group. For example, MA–ME 
genes are strongly enriched for terms related to sensory perception (Fig. 2.2c), whereas HA–HE 
genes are enriched for general cell functionality terms such as “cell cycle” and “RNA 
processing” (Fig. 2.2d). These findings are in agreement with previous studies. One such study, 
carried out in human T-helper cells, found that genes with accessible promoters and high 
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expression were enriched for housekeeping functions, whereas those with inaccessible promoters 
were enriched for olfactory terms [27]. A more recent study also found that genes with accessible 
promoters in three different types of hematopoietic stem cells (HSCs) were enriched for terms 
related to regulating the cell cycle and DNA damage and repair [28]. 
Figure 2.2. Promoter accessibility is strongly correlated with gene expression. a Scatter plot 
showing a strong positive correlation between promoter accessibility and gene expression. The 
correlation coefficient is shown in the red box (Spearman). b Genes are grouped based on the 
level of promoter accessibility and gene expression. The number of genes in each group is shown 
in the boxes. c Genes in the MA–ME group are enriched for biological processes related to 
sensory perception. The triangle at the end of the bar represents an FDR of 0. d Genes in the 
HA–HE group are enriched for biological processes related to housekeeping functions 
 
We next carried out binding site enrichment analysis on the promoters of genes in the 
MA–ME and HA–HE groups, using promoters of genes in the other three groups as background. 
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We identified multiple enriched motifs in the MA–ME group (Appendix B: Table 2.1), including 
those for Pou2f1 and Foxj2, which are associated with olfactory gene regulation and 
development [29, 30]. Many more motifs were enriched in the HA–HE group (Appendix B: 
Table 2.1), including several E2F and Ets motifs, which were previously found to be enriched in 
the promoters of housekeeping genes [31, 32]. 
Based on the enrichment of general cellular functionality terms and motif enrichment 
results, we predicted that a large number of housekeeping genes were in the HA–HE group. We 
therefore determined the percent overlap of MA–ME and HA–HE gene groups with 4781 
housekeeping genes identified across 17 tissues [33]. We found that 57% of the HA–HE group 
were annotated as housekeeping, while only 0.2% of the MA–ME group were annotated as 
housekeeping genes (Appendix A: Figure 2.7). 
In addition to MA–ME genes and HA–HE genes, we found 783 genes that had medium–
low accessibility and high expression (MA–HE), and 854 genes that had high accessibility and 
medium–low expression (HA–ME) (Fig. 2.2b). Because HA–ME and MA–HE genes are 
generally less understood, we further investigated how these two groups contribute to gene 
regulation in the placenta. 
HA–ME genes reveal a potentially repressed neuronal network 
Previous studies have identified regions of high accessibility that are also marked by a 
histone modification associated with gene repression, H3K27me3 [23, 34]. Therefore, we 
hypothesized that HA–ME genes may be actively repressed in the placenta. To identify potential 
transcription factors that may repress HA–ME genes, we scored motifs for transcription factors 
expressed in e9.5 placenta in HA–ME promoters using the PRISM [35] pipeline (see 
“Methods”). Three motifs were significantly enriched in HA–ME gene promoters relative to a 
background set of all gene promoters from each of the other three groups (Fig. 2.3a; Appendix B: 
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Tables 1, 2). The first enriched motif was for Sp2, a transcription factor that can repress 
cholesterol synthesis genes [36] and can form a repression complex with Klf6 to repress Mmp9 
[37]. The second enriched motif was for Setdb1, a histone methyltransferase that trimethylates 
lysine 9 on histone H3. Setdb1 is known to interact with Oct4 in embryonic stem cells (ESCs) to 
repress genes involved in differentiation [38, 39]. The third enriched motif was for the Rest/Nrsf 
transcription factor. Rest/Nrsf is well known to be involved in preventing neuronal 
differentiation and function in nonneuronal tissues [40,41,42]. To further investigate potential 
repression networks in HA–ME genes, we used the STRING database [43] (see “Methods”) and 
identified a large protein–protein interaction (PPI) subnetwork of 50 genes (Fig. 2.3b). 
Interestingly, the most highly connected genes in this subnetwork were Fzd4, Egf, and Syt1, of 
which Fzd4 and Egf are each known to be involved in neuronal differentiation [44,45,46,47]. To 
confirm the potential repression of genes in this network, we performed ChIP-qPCR for 
H3K27me3 on nine target genes from the network. We included genes that have a known role in 
neuronal differentiation, as well as those that have no known role in this process. All nine targets 
were bound by H3K27me3 (fold-change ≥ 1.5) and five were strongly bound (fold-change ≥ 10), 
indicating the genes are in a repressed state (Appendix A: Figure 2.8a). Next, we performed GO 
analysis of this network, which showed strong enrichment for terms such as “regulation of cell 
communication” and “cell–cell signaling” (Fig. 2.3c), which could be related to neuronal 
function. Using a randomization analysis (see “Methods”), we determined that these terms are 




Figure 2.3. Analysis of HA–ME genes. a Motifs that are enriched in HA–ME gene promoters 
compared to background gene promoters in e9.5 placenta. b The largest PPI network in the HA–
ME group, identified using STRING. Green nodes correspond to genes associated with the 
GREAT terms shown in c. c Bar plot of the enriched GO biological process terms for the 
subnetwork from b. Enriched terms are related to neuronal functions. d Tissue-specific gene 
enrichment analysis for genes in the subnetwork presented in b showing enrichment for genes 
expressed in brain-related tissues. Green colored bars correspond to tissues with an 




































































































































































































Finally, we used TissueEnrich [48] to determine whether the subnetwork was enriched 
for tissue-specific genes. We found the strongest enrichment for brain tissues, including the 
cortex and cerebellum (Fig. 2.3d). Together, these data provide strong evidence that a neuronal 
network is actively repressed in the placenta. 
Placenta-specific genes have medium–low promoter accessibility and high expression 
A large number of genes (783) were found to have medium–low promoter accessibility 
and high expression (Fig. 2.2b; Appendix A: Figure 2.9a). GO analysis of these genes showed 
enrichment for terms associated with placental functions, including “vasculature development” 
and “response to nutrient levels” (Fig. 2.4a). In order to determine whether these terms are 
enriched in the MA–HE group but not the HA–HE group because the HA–HE group is much 
larger, we performed a randomization analysis in which we sampled 783 genes from the HA–HE 
group 10,000 times and determined the enrichment of a subset of terms from Fig. 2.4a. We found 
that the FDR of these terms is consistently more significant in the MA–HE group than in the 
random sets from HA–HE, indicating that the large size of the HA–HE group is not masking the 
signal of these terms (Appendix A: Figure 2.9b–d). Since the GO terms were related to, but not 
specific to, placental functions, we also used TissueEnrich to perform tissue-specific gene 
enrichment analysis on the MA–HE group, which showed strong enrichment for placenta-
specific genes (Fig. 2.4b). 
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Figure 2.4. Analysis of MA–HE genes. a Bar plot of the enriched GO biological process terms in 
the MA–HE group, showing terms related to placental functions. b Tissue-specific gene 
enrichment analysis shows enrichment of placenta-specific genes in the MA–HE group. Colored 
bars correspond to tissues with an adjusted p value ≤ 0.01. c A network from GLay clustering of 
MA–HE genes. Orange nodes correspond to genes associated with the GREAT terms shown 
in d. d Bar plot of the enriched GO biological process terms in the network from c showing 
enrichment of lipid metabolism terms. 
Nucleosome formation potential has been found to be significantly higher in the 5′ 
regions of tissue-specific genes compared to housekeeping genes [49]. Therefore, we predicted 
that MA–HE genes would have higher nucleosome formation potential than HA–HE genes. We 
randomly chose 250 genes from each group and determined the nucleosome positioning scores 
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followed by the MA–HE group, and that the HA–HE group showed the lowest nucleosome 
formation potential [Appendix A: Figure 2.9e (left)]. To more thoroughly compare the HA–HE 
and MA–HE groups, we repeated the analysis using the entirety of the two groups and found a 
similar pattern and, as we predicted, MA–HE genes have significantly higher nucleosome 
positioning scores than HA–HE genes (p value < 2.2E−16) [Appendix A: Figure 2.9e (middle)]. 
This result was further confirmed using nuScore [51] to predict the average deformation energy 
across all sequences within a group. In agreement with the Recon results, we found that the MA–
HE group has a higher deformation energy than the HA–HE group [Appendix A: Figure 2.9e 
(right)]. 
Because the placenta has many roles and is composed of cell types with diverse 
functions, we wanted to determine whether the MA–HE group could be further divided into 
regulatory networks associated with specific placental processes. Using the STRING database, 
we identified a highly connected network of 318 genes, after which we implemented GLay 
community clustering [52] through Cytoscape [53]. GLay community clustering is an algorithm 
used to break up large, dense networks into highly connected clusters of interacting genes. GLay 
clustering resulted in 10 clusters of at least 10 genes. One such cluster (Fig. 2.4c) was enriched 
for terms related to lipid metabolism (Fig. 2.4d) and contained the lipoprotein lipase (Lpl) gene 
and several members of the apolipoprotein family including Apob, Apoa1, Apoa4, and Apoe. 
Many lipoproteins act as transporters for cholesterol throughout the body and across the placenta 
[54]. Lpl is mainly expressed in syncytiotrophoblast in humans [55] and decomposes 
lipoproteins into fatty acids. Interestingly, overexpression of Lpl affects nutrient transport and 
may result in severe intrauterine growth restriction [56]. In another cluster, Trp53, a gene which 
encodes the tumor-suppressing p53 protein and has been found to be increased in preeclamptic 
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placentas [57], was the hub node (Appendix A: Figure 2.9f). Many insulin-like growth factor-
binding proteins were also in this cluster, such as Igfbp4 and Igfbp5, which have been associated 
with preeclampsia and extra-villous trophoblast invasion [58]. These results demonstrate that 
integrating ATAC-seq data and RNA-seq data in the placenta can lead to the identification of 
distinct networks associated with different placental functions. These networks could be used to 
identify novel genes involved in the functions. 
Groups defined by accessibility and expression have consistent functions in multiple cell 
types 
To determine whether the functions we identified for the accessibility/expression groups 
can be generalized to other cell types, we ran our analysis pipeline on data from eight other 
mouse cell types: alpha cells [59], beta cells [59], embryonic stem cells (ESC) [60, 61], 
hematopoietic stem cells (HSC) [62], neuronal cells extracted from the dentate gyrus [63], retinal 
rods [64], lymphocytes from the spleen [65], and trophoblast stem cells (TSC) [66, 67]. First, we 
checked the correlation between the ATAC-seq promoter accessibility and RNA-seq TPM, 
which ranged from 0.658 to 0.799 (Appendix A: Figure 2.10). Based on the results from the 
placenta data, we predicted that sensory perception genes would be enriched in the MA–ME 
group in tissues and cells not associated with such functions and that genes important for general 
cellular functionality would be enriched in the HA–HE group of all of the cell types. Because of 
this, we expected that the MA–ME and HA–HE groups would have the highest number of 
common genes between the datasets. We compared the MA–ME genes between all nine of the 
datasets (including e9.5 placenta) and found a high degree of gene overlap, with a median 
pairwise overlap value of 83.5% (7295 genes) (Fig. 2.5a, b; Appendix A: Figure 2.11). Further, 
the top 20 enriched GO biological process terms for each dataset are similar and related to 
“sensory perception” and “G-protein coupled receptor protein signaling pathway” (Fig. 2.5c). A 
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similar analysis of HA–HE genes again showed high gene overlap between all datasets, with a 
median pairwise overlap value of 63.4% (2374.5 genes) (Fig. 2.5d, e; Appendix A: Figure 2.11). 
For HA–HE genes, the top 20 GO biological process terms for each set are similar and related to 
“RNA processing” and “protein transport” (Fig. 2.5f). 
For the HA–ME genes, the median pairwise overlap across all datasets was only 33.7% 
(177 genes), which is significantly lower than MA–ME genes (p value = 2.28e−13) and HA–HE 
genes (p value = 4.335e−12) (Fig. 2.5g, h; Appendix A: Figure 2.11). However, some of the 
datasets are enriched for terms related to “DNA packaging” (Fig. 2.5i). Interestingly, in addition 
to the placenta, only ESC and TSC HA–ME genes showed tissue-specific gene enrichment for 
brain tissues (cortex, cerebellum, olfactory bulb, e14.5 brain) (Appendix A: Figure 2.12a, b). As 
before, we used the STRING database to look at the protein–protein interaction networks within 
the HA–ME group from ESC and TSC. For ESC genes, we identified a large subnetwork of 121 
genes, enriched for neuron related terms such as “cell communication” and “signal transduction” 
(Appendix A: Figure 2.12c, d). A smaller subnetwork, comprised of 22 genes, was found in TSC 
HA–ME genes and was also enriched for signaling and neurotransmitter terms (Appendix A: 
Figure 2.12e, f). In addition to the subnetworks enriched for neuron associated functions, we 
found that Rest/Nrsf is as highly expressed in placenta and TSC as it is in ESC (Appendix A: 
Figure 2.12g). While Rest/Nrsf has been well characterized in ESC, where it prevents neuronal 
differentiation by repressing neuronal genes in order to promote stem cell pluripotency 
[68,69,70], its role in trophoblast cells and placenta is not well understood. Based on these 
results, we predict that similar repression mechanisms are shared in early placental cells and ESC 




















Figure 2.5. Integrating accessibility and expression data identifies tissue-specific genes in 
multiple cell types. a, d, g, j Bar plots showing the number of genes in each group for all tissues. 
The horizontal line marks the number of common genes between all tissues for each group, MA–
ME (a), HA–HE (d), HA–ME (g), or MA–HE (j). b, e, h, k Heatmap showing all genes of a 
particular group for all tissues as well as their corresponding group in other tissues. c, f, i, l The 
top 20 GO terms for each group in each tissue were identified. Then, the number of tissues each 
term appears in was calculated. The FDR of the term in all tissues in which it appeared was 
averaged. The terms contained in the top 20 of the most tissues and with the lowest FDR were 
plotted. The average FDR is shown, and the number of tissues the term appears in is indicated by 
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We next compared the MA–HE genes between datasets to determine whether genes with 
medium–low accessibility and high expression are always enriched for tissue-specific genes. For 
these genes, the median pairwise tissue overlap was only 21.5% (88 genes) which is significantly 
lower than MA–ME genes (p value = 2.815e−13) and HA–HE genes (p value = 2.381e−12) 
(Fig. 2.5j; Appendix A: Figure 2.11). Interestingly, of the 2836 genes that are MA–HE in at least 
one tissue, 1727 (~ 61%) are MA–ME in at least one other tissue, indicating that tissue-specific 
genes have low accessibility and expression in other tissues (Fig. 2.5k). We next determined 
which GO biological process terms and tissue-specific genes were enriched in the MA–HE group 
of each tissue. The low similarity between the biological process terms (Fig. 2.5l) and the high 
enrichment of tissue-specific genes in many of the tissues (Appendix A: Figure 2.13) support our 
previous result in the placenta, indicating that tissue-specific genes and processes are frequently 
enriched in the MA–HE group. 
To determine whether our findings uphold when analyzing human data, we repeated the 
analysis described above using primary human alpha and beta cells [24]. As with the other 
datasets, we found a positive correlation between the ATAC-seq promoter accessibility and 
RNA-seq TPM for both the alpha cells (0.636) and the beta cells (0.616). Similar to what we 
found in mouse, the MA–ME groups were enriched for sensory perception terms (Appendix A: 
Figure 2.14a, b), and the HA–HE groups were enriched for housekeeping functions (Appendix 
A: Figure 2.14c, d). Finally, we found that MA–HE genes from both cell types were enriched for 
pancreas-specific genes (Appendix A: Figure 2.14e, f), further supporting the conclusions that 
tissue-specific genes can be identified using this approach. 
Discussion 
In this study, we generated ATAC-seq data in the mouse placenta at e9.5, a time point 
shortly after branching morphogenesis has been initiated, when the vasculature is developing and 
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nutrient transport is active. In order to identify regulatory networks that activate or repress gene 
transcription at this time point, we integrated ATAC-seq data with RNA-seq data that were 
generated in the same context. Because previous studies have reported unexpected patterns with 
respect to promoter accessibility and the corresponding level of gene expression, we investigated 
this relationship more thoroughly in the placenta as well as in other tissues. 
In all tissues, we found a strong positive correlation between the promoter accessibility of 
a gene and its expression. Although there was a large set of genes contributing to that correlation, 
which showed consistent expression and accessibility patterns across the tissues, there were other 
genes that showed opposite patterns of promoter accessibility and expression. To further 
investigate this, we assigned genes to groups according to their expression and accessibility. We 
found that MA–ME genes, which have medium–low accessibility and medium–low expression, 
were enriched for sensory perception terms, not only in the placenta but in all of the cell types 
we analyzed. Genes with high accessibility and expression were enriched for terms important for 
general cellular functionality. Previous work has also found that genes with high accessibility in 
the promoter and high expression are frequently associated with housekeeping functions [27]. 
Despite the positive correlation between promoter accessibility and gene expression, 
many studies have indicated that low or decreasing expression is not always due to a lack of 
accessibility [18, 65, 66]. Others have also found an enrichment of ATAC-seq peaks not only in 
active regions, but in repressed regions, such as those marked by H3K27me3 [23, 24]. When we 
investigated genes with high accessibility and medium–low expression (HA–ME), we identified 
a neuronal network in the placenta, ESC, and TSC, potentially repressed by Rest/Nrsf. Rest/Nrsf 
is a well-studied transcription factor which, in addition to repressing neuronal gene expression, 
has also been described to protect against neurodegeneration [71]. In embryonic stem cells, 
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Rest/Nrsf has been found to help maintain pluripotency [70]. Using our pipeline, we were able to 
identify genes that are potential targets of Rest/Nrsf repression as well as validate H3K27me3 
activity within the promoter of nine of these targets. Future work could focus on the 
identification and validation of Rest/Nrsf targets in the placenta. 
While we also identified additional transcription factor motifs that were enriched in 
promoters of HA–ME genes or other gene groups, the true identity of the factors binding to these 
motifs would need to be confirmed with follow-up experiments, as many transcription factors 
have similar motifs. In general, ChIP-seq experiments for transcription factors identified in our 
analysis would allow in vivo identification of binding sites in gene promoters, as well as in distal 
regulatory regions, providing more insight into the mechanisms of gene regulation. 
Perhaps one of the most surprising results was that by integrating the level of 
accessibility at the promoter with the level of gene expression, we are able to distinguish 
between genes associated with housekeeping functions and genes associated with tissue-specific 
functions. Ontology enrichment analysis and tissue-specific gene enrichment analysis indicate 
that many genes within the MA–HE group are important for placental functions. There are 
multiple reasons that highly expressed genes could have medium–low accessibility. One is that 
tissue-specific genes have higher nucleosome forming potential than housekeeping genes, 
because they are more selectively accessible, as has been previously proposed [50]. This would 
likely result in lower ATAC-seq signal. To test this, we used Recon [50] and nuScore [51] and 
indeed found that MA–HE genes have higher nucleosome forming potential and greater 
deformation energy in the promoter than HA–HE genes. A second possibility is that the ATAC-
seq signal may be low due to the signal only being present in a subset of cells in a heterogeneous 
tissue, like the placenta. Therefore, we also investigated more homogeneous populations of cells, 
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such as dentate gyrus neurons and TSC. These analyses also identified MA–HE genes that are 
enriched for tissue-specific functions, indicating results are not specific to heterogeneous tissues. 
A third possibility is that large regulatory complexes binding at certain promoters prevent the 
transposase from accessing the DNA. Daugherty et al. [23] investigated binding sites of the 
EOR-1 transcription factor and found it occupying accessible and inaccessible regions. They 
hypothesized that EOR-1 may bind near nucleosomes, or as part of a larger complex preventing 
the transposase from accessing the DNA, causing the low signal at the binding regions. It is 
feasible that such mechanisms could lead to the low signal near the promoter regions of tissue-
specific genes. Along similar lines, it is possible that large regulatory complexes formed by 
enhancer–promoter interactions would make the promoter less accessible to transposase cutting. 
In general, further research incorporating additional data sets, as well as distal regulatory 
information, could help our understanding of the observed signal at tissue-specific genes. 
Conclusion 
In summary, we described a pipeline that is not only capable of identifying tissue-specific 
genes, but also networks of genes that may be actively repressed. This pipeline only requires two 
types of data, ATAC-seq and RNA-seq. Although many studies focus on strong ATAC-Seq 
peak, here we discover that a weaker signal of accessibility at the promoter may provide 
information about the gene’s role in a tissue-specific function. By applying this pipeline to the 
placenta at one time point, we were able to identify networks of genes associated with specific 
placental functions, as well as a potential actively repressed neuronal network. We also 
demonstrated that this analysis can be used in multiple tissues and cell types, in both mouse and 
human, to similarly identify actively repressed and tissue-specific genes. 
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Appendix A. Supplemental Figures 
Figure 2.6. ATAC-seq on whole tissues shows expected periodicity and correlations. (a) 
Representative bioanalyzer trace for an e9.5 ATAC-seq library prior to sequencing. Clear and 
even periodicity can be seen in the trace. (b,c) Histogram of fragment sizes for replicate 2 and 
replicate 3, showing expected periodicity. (d,e) Scatterplot comparing promoter accessibility 
between biological replicates. Pearson correlation is high between all replicates. 
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Figure 2.7. The HA-HE group contains a large number of housekeeping genes. The bar graph 
shows the number of genes in the MA-ME group and the HA-HE group that are considered 
housekeeping according to Bin Li et al. (2017) (black bar) and the total number of genes in each 




































Figure 2.8. The HA-ME group is marked by H3K27me3 and is associated with neuronal 
functions. (A) H3K27me3 ChIP-enrichment relative to Gapdh in promoters of HA-ME genes. 
Bar plot shows mean enrichment of the nine tested genes, error bars indicate standard deviation. 
ChIP was performed for 3 biological replicates. (B-D) Bar plots representing the –log10 (FDR) of 
the specified term from random subgroups of HA-ME genes. The green line denotes the –log10 
(FDR) of the term in the subnetwork from Figure 2.3C in the main manuscript. 
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Figure 2.9. The MA-HE group is enriched for tissue-specific genes. (A) Representative genes 
from the MA-HE group. ATAC-seq track, displayed in red, shows low accessibility. (B-D) Bar 
plots representing the –log10 (FDR) of the specified term from random subgroups of HA-HE 
genes. The orange line denotes the –log10 (FDR) of the terms in the MA-HE group. (E) Recon 
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score distribution for 250 randomly chosen genes from each of the four groups (left). Recon 
score distribution for the entire HA-HE and MA-HE groups (middle). MA-HE genes have 
significantly higher nucleosome positioning scores than HA-HE (middle; **** represents p-
value < 0.0001, Mann-Whitney U test). NuScore deformation energy for all of the genes in all of 
the groups (right). MA-HE genes have a higher deformation energy than HA-HE genes. (F) MA-
HE gene cluster identified by the GLay community clustering algorithm. Color intensity 




Figure 2.10. 3ATAC-seq and RNA-seq show high correlation in all tested cell types.Spearman 
correlations (column 2) between promoter accessibility and RNA-seq TPM are high in all cell 













Figure 2.11. Pairwise comparison of genes in each group for all tissues. Boxplots illustrate the 
distribution of pairwise percent overlap of genes between all pairs of tissues for each group 






















Figure 2.12. HA-ME genes in ESC and TSC have potentially repressed neuronal networks. (A) 
Tissue-specific gene enrichment analysis showing that the ESC HA-ME group is enriched for 
genes specifically expressed in multiple tissues, including the brain (E14.5 brain, olfactory bulb, 
cerebellum, and cortex). Colored bars correspond to tissues with an adjusted p-value ≤ 0.01. (B) 
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Tissue-specific gene enrichment analysis showing that the TSC HA-ME group is enriched for 
genes specifically expressed in multiple tissues, including the brain (E14.5 brain, olfactory bulb, 
cerebellum, and cortex). Colored bars correspond to tissues with an adjusted p- value ≤ 0.01. (C) 
PPI network obtained from genes in the ESC HA-ME group. Colored nodes represent genes 
related to the GO terms in (D). (D) Bar plot of the enriched GO biological process terms for the 
subnetwork from (C). Enriched terms are related to neuronal functions. (E) PPI network 
obtained from genes in the TSC HA-ME group. Colored nodes represent genes related to the GO 
terms in (F). (F) Bar plot of the enriched GO biological process terms, from STRING, for the 
subnetwork from (E). Enriched terms are related to neuronal functions. (G) Rest/Nrsf expression 

















Figure 2.13. Tissue-specific gene expression in MA-HE groups. Tissue-specific gene enrichment 
analysis for the MA-HE group of each tissue showing that for most tissues, there is an 
enrichment of genes specifically expressed in those tissues. Retina and pancreatic cell data are 
not part of the mouse Encode data, which was used for tissue-specific gene enrichment analysis. 




Figure 2.14. Group analysis of human alpha and beta cells. (A,B) Genes in the MA-ME group of 
human alpha and beta cells are enriched for biological processes related to sensory perception. 
(C,D) Genes in the HA-HE group of human alpha and beta cells are enriched for biological 
processes related to housekeeping functions. (E,F) Tissue-specific gene enrichment analysis 
shows enrichment of pancreas-specific genes in the MA-HE group for both alpha and beta cells. 
Colored bars correspond to tissues with an adjusted p-value ≤ 0.01. 
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Appendix B. Supplemental Tables 





Fold FDR Origin of Motif Similar motifs 
MA-ME 
     
T_POU2F1_db
d_02 
586 2.35 0.00E+00 Taipale[1] 
 
V_FOXJ2_02 591 2.19 0.00E+00 Transfac[2] 
 
V_TEF_Q6 576 2.36 0.00E+00 Transfac 
 




99 2.70 1.36E-04 Taipale 
 








73 2.54 6.52E-03 Taipale 
 
      
HA-HE 
     
B_Plagl1_prim
ary 
1848 2.01 0.00E+00 Bulyk Uniprobe[3] V_PLAGL1_03 
G_CHREBP_M
LX_01 
917 2.30 0.00E+00 Genomatix[4] T_MAX_dbd_01 








1656 3.23 0.00E+00 Genomatix 
 
G_HES1_02 792 2.32 0.00E+00 Genomatix 
 
R_HIF1A_p2 1330 2.58 0.00E+00 SwissRegulon[5] 
 
R_TFDP1_p2 3310 2.86 0.00E+00 SwissRegulon B_E2F2_primary,V_E
2F2_03,V_E2F3_03,B
_E2F3_primary 
S_ATF3_disc2 929 3.66 0.00E+00 Stamatoyannopoulos[6] 
 
S_Myc_disc6 284 2.14 0.00E+00 Stamatoyannopoulos 
 
S_Nrf1_disc2 1809 2.16 0.00E+00 Stamatoyannopoulos 
 













S_SP1_disc3 2697 2.20 0.00E+00 Stamatoyannopoulos 
 
S_SP2_disc2 325 4.50 0.00E+00 Stamatoyannopoulos 
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Table 2.1 Continued 
 # of 
Binding 
Sites 
Fold FDR Origin of Motif Similar motifs 
S_TCF12_disc3 2988 2.18 0.00E+00 Stamatoyannopoulos S_ZBTB7A_disc2,S_
SP2_disc3 




















1947 2.75 0.00E+00 Stamatoyannopoulos S_RXRA_disc2 
T_Creb3l2_dbd
_02 
281 3.51 0.00E+00 Taipale T_CREB3L1_full_01 
T_E2F1_dbd_0
2 











207 3.47 0.00E+00 Taipale T_ETS1_full_02 
T_ETV6_full_0
1 












2177 2.08 0.00E+00 Taipale T_ZBTB7B_full_01,V
_ZBTB7B_04 
V_DEAF1_01 437 3.85 0.00E+00 Transfac V_DEAF1_02 
V_E2F1_Q3_0
1 
3193 2.89 0.00E+00 Transfac V_E2F1_Q6_01,V_E2
F1_Q4_01,R_E2F1_5
_p2 
V_E2F1_Q4 2657 2.54 0.00E+00 Transfac 
 
V_E2F4_Q6 3192 2.87 0.00E+00 Transfac 
 
V_MAF_Q6 540 2.47 0.00E+00 Transfac 
 
V_MECP2_01 3148 2.80 0.00E+00 Transfac 
 
V_MECP2_02 3065 2.96 0.00E+00 Transfac V_ELK1_05,L_ELK1
_02 
V_PLAG1_02 1222 2.14 0.00E+00 Transfac 
 
V_SP2_01 2512 2.73 0.00E+00 Transfac G_SP2_01 
V_ZBTB7C_Q
2 
2459 2.43 0.00E+00 Transfac 
 
      
HA-ME 
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Table 2.1 Continued 
 # of 
Binding 
Sites 
Fold FDR Origin of Motif Similar motifs 




74 2.05 2.88E-06 Stamatoyannopoulos 
 
V_REST_01 33 2.21 4.94E-03 Transfac 
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Table 2.2. Enriched motifs in HA-ME promoters 
Gene Name Gene 
Symbol 
Fold Q-value Placenta 
TPM 
Transcription Factor Sp2 Sp2 2.29 9.16E-08 40.11 
SET domain, bifurcated 1 Setdb1 2.05 2.88E-06 23.92 
RE1-silencing transcription factor/ 
Neuron-restrictive silencer factor 
Rest/Nrsf 2.21 4.94E-03 216.02 
Table 2.3. Nextera adapters used for ATAC-seq 
  Nextera 
Adapters 
Bases in 5xx adapter Bases in 7xx adapter 
 
Replicate 1 504/703 AGAGTAGA AGGCAGAA 
 
Replicate 2 517/705 GCGTAAGA GGACTCCT 
 







Table 2.4. Read counts for ATAC-seq data 
   Rep Original Mapped ChrM MapQ 
(<20) 
Paired Duplicates Final 
Alpha 1 50715221 50181062 29040674 21441499 20387582 18377868 17796516 
2 56419963 55953405 25971313 17831175 16990726 15376200 14911082 
3 87228371 86288699 45684302 31177219 29983453 27918944 27060568 
4 94963259 94027956 52803950 37112303 35889629 33342448 32444058 
5 93809083 92791998 51325866 35636489 34388815 32083113 31172142 
Beta 1 99138455 98255253 48311331 33778973 32756671 29364422 28622684 
2 56053549 55655922 27168343 19911631 19130263 14224508 13817682 
3 54612435 54291150 31798039 25368133 24359489 21499478 20966738 
4 102463765 101617528 58467519 43554672 42357661 39337621 38464854 
5 92952729 92266413 40992093 27098811 26271255 22826145 22221356 
ESC 1 72395177 70382159 58921562 48848937 48139095 24946762 24252196 
2 67404777 65795453 57843059 48469385 47713891 13656980 12954262 
3 65771929 64185289 56365406 47276157 46540168 13957820 13278782 
HSC 1 89739159 83025131 72323563 60962965 57900117 43295928 42653008 
2 111515887 101024535 84834533 70977502 68001269 53837098 53070228 
Neuron 1 14378411 12608838 11270022 9683097 9320903 8989157 8941274 
2 19320173 16836605 15381313 13330162 12798530 12337334 12269596 
3 31239879 28284669 9544772 4809851 4727813 4425192 4367666 
4 43400971 39473442 13087525 6418279 6308368 5870977 5797058 
Placenta 1 93429183 86515054 44895514 28027180 26446025 20837499 20605946 
2 73361953 65558919 34893398 21921487 20539578 16645842 16458968 
3 80502611 72966154 40961196 26707725 25193436 19620268 19387954 
Retina 1 56063268 47474455 46678303 42037092 40207145 37570211 37141478 
2 72922574 60871937 58872615 53012191 50802357 47211975 46647812 
Spleen 1 48417187 45854373 39978922 31931910 30312282 14551002 13779288 
2 59247937 55504576 40173629 31351203 30747214 28243472 27730004 
3 63385029 59049526 42377291 32875690 32280420 29823878 29316988 
TSC 1 137425125 130654686 58660552 38983217 37708370 26989464 26168696 
2 130699325 128073691 63656329 44626343 43205426 31872395 30847506 
Alpha 
(hg19) 
1 356469002 337197506 241059476 193622284 183230652 147257022 144303136 
2 366011950 352035544 196613938 154778416 147339516 129881322 127347598 
Rep 3 320137988 312958518 107432658 80313670 76705925 71730761 69828580 
Beta 
(hg19) 
Rep 1 407887442 386497812 173903004 129913315 123796851 105210081 103181250 
Rep 2 444082308 421426167 250950962 187962713 175451529 150493813 147975166 
Rep 3 379994294 371871169 97788329 64742661 61842239 57678369 56018348 
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Table 2.5. Datasets used for ATAC-seq analysis 
Cell/Tissue Accession ID Read Length Bowtie2 alignment 
(%) 
Alpha* GSE99954 35-76 97.2 
Beta* GSE99954 35-76 99.25 
ESC GSE87548 51 97.47 
HSC* GSE87527 36-75 91.56 
Neuron GSE82015 50 89.08 
Placenta GSE120599 50 90.7 
Retina GSE83312 50 84.65 
Spleen GSE88987 35-50 93.85 
TSC* GSE94694 36-75 96.53 
Alpha (hg19) GSE76268 41-50 95.72 
Beta (hg19) GSE76268 41-50 95.24 
    
Read length is reported after trimming (* indicate reads were trimmed). 
The Bowtie2 overall alignment is averaged across biological replicates. 
Table 2.6. Datasets used for RNA-seq analysis 
Cell/Tissue Accession ID Read Length HISAT2 alignment 
(%) 
Alpha GSE99954 75 95.67 
Beta GSE99954 75 93.08 
ESC* GSE66390 36-126 73.31 
HSC GSE87527 50 90.15 
Neuron* GSE82015 36-97 87.57 
Placenta GSE65808 100 96.9 
Retina GSE83312 50 86.83 
Spleen GSE88987 50 91.2 
TSC GSE78782 101 95.5 
Alpha (hg19)* GSE76268 36-100 97.19 
Beta (hg19)* GSE76268 36-100 96.26     
Read length is reported after trimming (* indicate reads were trimmed). 




Table 2.7. H3K27me3 primers 
Gene Forward Reverse Efficiency 
Scg3 ccaaaggaaccccattctttc aagagcctgcatcctccttc 88.38% 
Syt1 aagttgcccactgctaactgc gctgtggggatggagagact 91.63% 
Syt9 cgcgctttccaagtttaaaga atgcaaacctagcatccctca 99.69% 
Dnajc6 caggcgtctttcacttccaac aggggagaaggtgtcttggag 96.50% 
Htr5b gaccttccctgaatggttgct accgctgctagctttctctcc 94.64% 
Ryr2 cccatttctaaggccttttgg cgtatggagggagtcgaagtg 93.77% 
Fzd4 tgtaaggggaaggacgtgaaa aacgcgactgtccaatgaaag 86.86% 
Egf cgagcaaaggagggagaagat ttttgacaagtggcaggaggt 98.12% 
Scg2 atattatgtggaaggctccaag tctctataagccgaggagctg 100.60% 






CHAPTER 3.    ANNOTATING CISREGULATORY ELEMENTS WITHIN THE 
MIDGESTATION MOUSE PLACENTA 
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Modified from a manuscript to be submitted to Scientific Reports  
Abstract 
The placenta is a temporary, vital organ which provides the developing fetus with 
nutrients, oxygen, and protection in utero. Defects in its development, commonly caused by 
misregulated gene expression, can lead to devastating outcomes for both the mother and fetus. In 
mouse, placental defects commonly lead to embryonic lethality during midgestation. However, 
the regulatory mechanisms necessary for proper spatiotemporal expression of genes during this 
time have not been thoroughly investigated. 
To better understand transcriptional regulation, we generated several ChIP-seq datasets 
targeting histone modifications known to characterize cis-regulatory regions. By incorporating 
the newly generated ChIP-seq data with published ChIP-seq data, we were able to annotate  
regulatory regions, such as enhancers and promoters, throughout the genome. Not only were we 
able to locate such regions, but we also characterized their activity as active or poised. Using 
computational methods, we predicted which genes these regulatory regions targeted and 
analyzed their function. We found that poised promoters tend to be near genes involved in 
neuronal development while a large portion of active promoters are at housekeeping genes. 
However, active and poised enhancers show enrichment for genes involved in placental 
development, though only the active enhancers show enrichment for placenta-specific genes. We 
identified motifs enriched within the active enhancers and found a large network of transcription 
factors which may be regulating these regions. Interestingly, one of these transcription factors, 
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BHLHA15, shows placenta-enriched expression and is predicted to target genes implicated in 
placental development, but it’s role in placenta has yet to be fully understood. 
This work provides a valuable resource for researchers – allowing them to identify 
regulatory regions, or important genes for further study, aiding in our overall understanding of 
the placenta.   
Introduction 
The placenta is an essential organ during development, providing the fetus with adequate 
nutrients, oxygen, and protection during gestation. Disfunctions in genetic regulation within the 
placenta can have detrimental effects on the health of the mother and fetus, as well as lead to a 
variety of placental disease such as preeclampsia1, placenta accreta2, or even miscarriage3. 
Mouse is a commonly used model to understand the genetic regulations governing the 
development and function of the human placenta. Within the mouse, genetic mutations 
commonly lead to embryonic lethality from embryonic day (e)9.5 – e14.54,  emphasizing the 
importance of studying gene regulation in the mid-gestation placenta. 
Several factors contribute to gene regulation, including transcription factors, cis-
regulatory elements, and epigenetic modifications. Post-translational modifications have been 
identified on histones, proteins necessary to pack and order DNA, which have been found to be 
important for the regulation of gene expression in response to environmental stimuli and 
development. Perturbations in histone modifications can alter the structure of chromatin, 
preventing interactions between specific regulating chromatin factors5 and have been implicated 
in development6 and cancer7.  
Histone acetylation is generally associated with gene activation. Acetylation of the 27th 
lysine of the third histone (H3k27ac) has been found to be enriched in the promoter of active 
genes and within active enhancers8–10, distinguishing such regions from poised enhancers9. 
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Methylation of the same lysine (H3k27me3) has been generally associated with gene 
repression8,11. However, methylations of the 4th lysine (H3k4me1/H3k4me3) have instead been 
associated with specific genetic regions, rather than gene activity. H3k4me3 has been found to be 
enriched at the transcription start site (TSS) of active genes10 while H3k4me1 has been found to 
mark enhancers9,10,12.  
Though each histone modification individually contributes to our understanding of gene 
regulation, when combined, these modifications can annotate the genome with more detail. For 
example, though H3k4me1 marks enhancers, H3k27ac with H3k4me1 identifies active 
enhancers9. H3k4me3 has been found near both H3k27ac and H3k27me3 marks, the latter 
marking bivalent regions generally thought to indicate poised genes important for development13.   
Previous studies have examined various histone modifications in order to better 
understand the regulatory landscape of the mouse placenta. One study by Shen et al.14 combined 
several datasets including RNA-seq and ChIP-seq of several histone modifications, RNA 
polymerase II, and CTCF, across 19 tissues, including the e14.5 placenta,  in order to identify 
tissue-specific enhancers and promoters. Another study examined histone modifications to 
identify promoters and enhancers in mouse and rat trophoblast stem cells15, focusing on 
identifying differences in the species-specific enhancers to gain insight on placental evolution. 
However a thorough investigation of the e9.5 placenta, an important time in development when 
the labyrinth is developing to allow adequate exchange of material16, has not been done.  
Therefore, to identify cis-regulatory elements involved in gene regulation within the e9.5 
placenta, we  performed ChIP-seq to identify regions marked with H3k27me3, H3k4me1, and 
H3k4me3 modifications. Using these data and a published H3k27ac ChIP-seq dataset17, we 
employed ChromHMM18 to annotate the e9.5 placental genome, identifying potential repressors, 
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enhancers, active promoters, and bivalent regions. Overall, these data provide a valuable 
resource for researchers trying to understand gene regulation of the mid-gestation placenta.  
Methods 
ChIP-seq library preparation and sequencing 
Whole placentas were dissected from e9.5 timed-pregnant CD-1 mice (Charles Rivers 
Labs). All animal experiments were approved by the Iowa State University Institutional Animal 
Care and Use Committee (Protocol IACUC-18-350) and conformed to the NIH Guidelines for 
the Care and Use of Laboratory Animals. Three placentas were combined per biological replicate 
for chromatin isolation as described19. ChIP-seq was then performed as previously described for 
H3K27me319 with 10ug of chromatin and 4ug of H3K27me3 antibody (Millipore 17-622, 
lot:3070997) for a total of 4 biological replicates. H3K4me1 and H3K4me3 ChIPs were 
performed as previously described20 with the following modifications: 2.5ug of chromatin was 
precleared with 80ul of Protein G-agarose (Thermofisher 20422) in 1ml of ChIP dilution buffer 
and incubated over night with 2 ug of H3K4me1 antibody (Abcam ab8895, lot: GR3264996-2) 
or 0.5ug of H3K4me3 antibody (Abcam ab8580, lot: GR3264593-1), generating 6 biological 
replicates for each antibody.  
Chromatin was simultaneously prepared as input DNA for each replicate. The enrichment 
level for each histone modification was quantified using Real-Time qPCR with input DNA for 
normalization and enrichment calculations using the DDCt method with 28S reference primers 
and input DNA. Syt1 (H3K27me3), B4galt5 (H3k4me1), and Ldha/Gapdh (H3k4me3) (primers 
in Appendix B: Table 3.1; Appendix A: Figure 3.5) were used as positive controls. Efficiency of 
primers was calculated by testing 4 fold serial dilutions of input DNA (Appendix B: Table 3.1).  
ChIP-seq libraries were performed as previously described21 with the following 
modifications: 40ul (80%) of the purified ChIP DNA was used for library preparation of each 
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biological replicate and gel size selection was performed by excising DNA fragments between 
250bp – 350bp. 5ng of input sample libraries were also prepared simultaneously as controls. 
Libraries were run on Agilent 2100 bioanalyzer using the high sensitivity DNA kit to ensure 
proper size selection. Both ChIP and input libraries were diluted to 4nM concentration and 
pooled together. Further dilution of the samples and sequencing on Illumina HiSeq 3000 was 
performed by Iowa State University DNA facility. 
ChIP-seq data processing 
ChIP-seq data for the H3k27ac associated histone mark was obtained from GEO 
(GSE6580717). Read quality for all ChIP samples was determined using FASTQC22(v0.11.7) and 
reads were aligned to the mm10 genome using Bowtie223(v2.3.4.1; --very-sensitive). All samples 
had high average overall alignment rates (Appendix B: Table 3.2). After reads were aligned, they 
were filtered to remove reads with low mapping quality (£30 MapQ), those that align to the 
mitochondrial genome, and duplicates (Picard v2.5.0; http://broadinstitute.github.io/picard).  
ChIP-seq data analysis 
Filtered Bowtie2 sam files were used in ChromHMM18(v1.20) with 13 states, using 
corresponding mouse input DNA as control. The sam files were also used for peak calling with 
MACS224(v2.1.1), either broad peaks(H3k27me3; --broad -g mm -f BAM -q 0.05 --bdg --keep-
dup all) or narrow peaks (Hk372ac, H3k4me3, H3k4me1; -g mm -f BAM -q 0.05 --bdg --keep-
dup all). Peaks within 500bp were merged together using bedtools225(v2.27.1; merge) and peaks 
were retained if they occurred in at least half of the corresponding biological replicates and did 
not overlap blacklisted regions26. After regions were assigned to states by ChromHMM, they 
were further intersected with MACS2 peaks, and only regions containing the appropriate histone 
mark were kept for further analysis. For the repressed (R) state, ChromHMM regions containing 
an H3k27me3 peak were retained. For the active enhancer (AE) and poised enhancer (PE) states, 
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an H3k4me1 peak must be present within the ChromHMM region. For the active promoter (AP) 
and poised promoter (PP) states, an H3k4me3 peak must be present. The genomic location of 
ChromHMM regions and their location in relation to TSSs were identified using the R package 
ChIPseeker(v1.24.0). 
ATAC-seq data processing 
E9.5 placenta ATAC-seq data was obtained from GEO (GSE120599) and processed as 
previously described19. After removing duplicates, MACS2 (-f BAMPE -g mm --keep-dup all -q 
0.05) was used to call narrow peaks. Peaks overlapping blacklisted regions were removed and 
peaks within 100bp of each other were merged. Only peaks that were in at least two of the three 
replicates were kept for analysis.  
RNA-seq data processing 
E9.5 placenta RNA-seq data was obtained from GEO (GSE6580817) and processed as 
previously described19. Reads were aligned to the mm10 mouse genome using HISAT2 (v2.2.0; 
default parameters) and transcript per million (TPM) was calculated27 after quantifying transcript 
abundance by htseq-count from the HTseq28 software package. TPMs for each gene were then 
averaged across biological replicates. Sets of gene expression were compared using the students 
one-tailed t-test. 
Gene Ontology and gene associations 
Gene ontology enrichment analysis and gene associations with state regions were 
performed using the Genomic Regions Enrichment of Annotations Tool (GREAT29 v4.0.4). The 
biological process ontology and the MGI Single Phenotype KO ontology were used for analysis. 
For regions associated with promoters, we used the single nearest gene option, associating each 
region with its nearest gene, and terms were considered significantly enriched if they had a 
‘Hyper FDR Q-Val’ £0.05, a ‘Hyper Fold Enrichment’ ³ 2 and were associated with at least 5 
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genes. For distal regions, default GREAT options were used for gene association and enriched 
terms had to have a  ‘Binom FDR Q-Val’ £0.05 a ‘Binom Fold Enrichment’ ³ 2 and were 
associated with at least 5 genes. For all figures, the top terms based on FDR are shown.  
Transcription factor and network analysis 
Enrichment of transcription factors within active enhancer regions was determined using 
HOMER30(v4.11.1; findMotifsGenome.pl –genome mm10) known motif finding software and 
the mm10 genome. Only significant (q-value £0.01) transcription factors found were kept for 
analysis. Mouse transcription factors were identified using the Animal Transcription Factor 
Database31 (v3.0). Targets of enriched transcription factors were also identified using the 
HOMER software(findMotifsGenome.pl -find).   
The STRING database32(v11.0) was used to build protein-protein interaction networks 
from enriched TFs. Networks were built with a confidence threshold of 0.40 and using all forms 
of evidence. Networks were analyzed using Cytoscape33(v3.8.0) and hub nodes were defined as 
the top 3 nodes with the highest degree or betweenness score.  
 
Tissue-specific gene enrichment 
TissueEnrich34 was used to carry out tissue-specific gene enrichment analysis using all of 
the tissue-specific genes from the mouse ENCODE data as background and default parameters. 
Tissue-specific gene sets with an adjusted p-value £ 0.01 were considered enriched, using the 
hypergeometric test.  
Results 
ChromHMM defines cis-regulatory regions throughout the mouse genome 
In order to analyze the interplay of certain histone modifications and to understand gene 
regulation within the murine midgestation placenta we generated ChIP-seq data for three histone 
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marks in the e9.5 placenta. We focused on histone modifications known to be associated with 
genomic regions with different regulatory functions: H3k27me3(facultative heterochromatin 
5,10,11), H3k4me1(enhancers5,10,12), and H3k4me3 (promoters5,10,12). We also used previously 
published H3k27ac17 ChIP-seq data, which marks active enhancers9,10 and promoters8,10.  
We utilized ChromHMM18 in order to associate each region of the genome with one of 
13 states, based on the presence of aligned reads for each histone modification in the region 
[Figure 3.1a]. ChromHMM works by discovering combinatorial patterns of histone marks 
throughout the genome by applying a multivariate hidden Markov model, based on the presence 
or absence of each histone mark. Regions containing the same pattern of histone marks are 
placed in the same state. To map the ChromHMM state to an actual chromatin state with a cis-
acting function (e.g. promoter, repressor, enhancer), we looked more closely at the histone 
modifications present in certain states, as well as the location of the regions within the state. We 
focused on states containing certain histone modifications or sets of modifications that are well 
characterized (State 2, 4, 5, 8, 10). In doing this analysis, we also incorporated peaks identified in 
each dataset by MACS2, retaining regions which contain a significant peak (details in methods).  
We first analyze state 2 which contained only high H3k27me3 activity. We find this state 
is distributed across the genome [Figure 3.1b(top)], consistent with a previous study which found 
a similar pattern for the H3k27me3 mark35. This indicates that state 2 is associated with gene 
repression (R).  An example of a genomic region in the R state is shown around the Hoxa cluster 
of genes, which are globally silenced during development36 [Figure 3.1b(bottom)]. State 4 
regions contained high levels of H3k27me3, H3k4me1, and H3k4me3 activity. We found that 
these regions were most commonly within promoter regions [Figure 3.1c(top)], most likely 
representing poised promoters (PP), which have previously been found to be marked by these 
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modifications37. An example of a genomic region in the PP state is shown at the Tfap2a gene 
[Figure 3.1c(bottom)], which plays a role in trophoblast differentiation38. State 5, on the other 
hand, has H3k27me3 and H3k4me1 activity, as well as very low H3k4me3 activity, and contains 
regions at promoters, but more frequently, within intergenic and intronic regions [Figure 
3.1d(top)], potentially marking these regions as poised enhancers (PE). An example of a genomic 
region marked by the PE state is shown just upstream of the Shd gene region [Figure 
3.1d(bottom)]. State 8 regions have both H3k27ac and H3k4me1 activity, a pattern which has 
previously been found at active enhancers9. The majority of this state is found within intergenic 
and intronic regions [Figure 3.1e(top)]. This indicates that state 8 marks active enhancers (AE), 
one of which can be found downstream of the H19 gene at its enhancer39 [Figure 3.1e(bottom)]. 
H19 is an imprinted gene which may play a role in trophoblast proliferation and invasion40. 
Lastly, state 10 regions contain high H3k27ac and H3k4me3 signals, marks previously shown to 
indicate active promoters10,37,41. Regions within this state are most commonly found in promoter 
regions [Figure 3.1f(top)],  therefore, state 10 is associated active promoters (AP). For example, 
a region in the AP state can be found at the TSS of the housekeeping Polr2a42 [Figure 
3.1f(bottom)]. We created publicly available session (e9.5Placenta_HistoneModification) in the 
UCSC genome browser containing the averaged ChIP-Seq read tracks for each histone 




Figure 3.1.ChromHMM identifies promoters and enhancers throughout the mouse placental 
genome. (a) ChromHMM heatmap displaying the amount of activity of each histone 
modification within the identified states. (b-f) Top: Genomic locations of regions within each 
analyzed state.  Bottom: UCSC Genome Browser shot showing an example of a genomic region 
associated with each analyzed state. b. State 2 (R) c. State 4 (PP) d. State 5 (PE) e. State 8 (AE) 
f. State 10 (AP) 
 
 
Poised and active promoter states are associated with distinct gene sets 
First, we investigated genes associated with the PP state. We performed gene ontology 
enrichment analysis and found nervous system and neuron development terms enriched for genes 
associated with the PP state [Figure 3.2a], and many of these genes show expression specific to 
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brain tissues [Figure 3.2b]. However, previously poised or bivalent promoters in embryonic stem 
cells were found to mark transcription factors important for development43.  Though we found 
several neuronal genes in the PP State, we also found a subset of genes that code for TFs with 
roles in early development, including stem cell differentiation (SATB244), trophoblast 
differentiation (HAND145, ASCL246, TCFAP2A38), and trophoblast invasion (FOSL147). 
Next, we investigated genes associated with the AP state. We found that the AP state 
genes show enrichment for general cell functionality terms [Figure 3.2c] and no tissue-specific 
expression [Figure 3.2d], potentially indicating a high number of house-keeping genes. Previous 
studies have found that genes with housekeeping functions have narrow H3k4me3 peaks at the 
TSS48 or highly accessible regions within their promoter19,49. Therefore, using previously 
published ATAC-seq19 data generated in the e9.5 placenta, we overlapped the accessible peaks 
with each of the 5 analyzed states and found that the AP state has a much higher percentage of 
regions overlapping accessible regions than all the other states, further indicating a house-
keeping status [Appendix A: Figure 3.6a]. We then overlapped a list of housekeeping genes50 
with each of the states and once again find highest overlap within AP state genes (~46%) 
[Appendix A: Figure 3.6b], further confirming that the strong H3k27ac and H3k4me3 signal of 
the AP state tend to mark housekeeping genes. 
When comparing expression between AP and PP state genes, we see that poised 
promoters have significantly lower expression than active promoter genes (p-value< 2.2e-16), 
containing several house-keeping genes, as expected [Appendix A: Figure 3.6c].  
 90 
 
Figure 3.2. Poised promoters are associated with neurogenesis while active promoters tend to 
mark housekeeping genes. (a) Genes associated with poised promoters are enriched for 
biological processes related to neuron development. (b) Genes associated with the PP state are 
mostly enriched for brain genes (cortex, e14.5 brain, cerebellum, and olfactory bulb). (c) Genes 
associated with active promoters are enriched for biological processes related to general cellular 
functionality. (d) Genes associated with the AP state are not specific to any tissue, potentially 
indicating house-keeping genes.  
 
Analysis of Enhancer States shows association with placenta development 
Next we investigated the function and expression level of genes associated with the non-
promoter states, i.e. potential repressive and enhancer regions. We found that genes associated 
with regions in the R state were enriched for terms related to pattern specification, spinal cord 
development, and neurotransmitter transport [Figure 3.3a]. This set was also enriched for genes 
with brain-specific expression [Figure 3.3b]. These results agree with a previous study that 
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regions in the AE and PE states are associated with placental development, however, those 
associated with active enhancers are enriched for actin cytoskeleton and cell junction 
organization as well [Figure 3.3c,e], processes important for trophoblast cell differentiation and 
cellular adhesion51,52. When using the Mouse Phenotype Single KO ontology, we see several 
terms related to placenta morphology and embryonic lethality associated with the AE state genes, 
whereas placenta terms were not enriched for PE state genes [Appendix A: Figure 3.7a,b]. Tissue 
enrichment further showed that AE state genes are placenta-specific [Figure 3.3d], whereas the 
PE set contained genes that were specific for multiple tissues [Figure 3.3f]. This is expected 
since active enhancers are known to drive tissue-specific gene expression53.  
When we compare the expression of the non-promoter states, we see that genes in the AE 
state have the highest expression, significantly higher than the PE state (p-value < 2.2e-16) and, 
unsurprisingly the R state genes (p-value < 2.2e-16) [Appendix A: Figure 3.7c]. 
Identification of Transcription factors regulating AE regions 
Because enhancers generally drive tissue-specific gene expression53, we further 
investigated the TFs potentially regulating these regions, focusing on intergenic and intronic 
regions of active enhancers states within the e9.5 placenta. Using Homer, we searched known 
motifs enriched in the regions associated with the AE state. We only analyzed TFs with an FDR 
≤ 0.01 and found several TFs enriched within the active enhancers [Appendix B: Table 3.3]. 
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By analyzing the protein-protein interaction network via STRING, we discovered a 
network of 71 TFs [Figure 3.4a] from the 75 enriched mouse TFs associated with the active 
enhancers. The most connected TFs in this network were MYC, FOS, JUN, and GATA4, most of  
Figure 3.3. Repressed regions are associated with neuronal terms while enhancers are associated 
with placenta development. (a) Genes associated with repressed regions are enriched for 
biological processes related to spinal cord development and pattern formation. (b) Genes 
associated with the R state are mostly enriched for brain genes (cortex, e14.5 brain, cerebellum, 
and olfactory bulb). (c) Genes associated with active enhancers are enriched for biological 
processes terms related to placenta development and cytoskeleton organization. (d) Genes 
associated with the AE state are strongly enriched for placenta genes. (e) Genes associated with 
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poised enhancers are enriched for biological processes terms related to placenta development. (f) 
Genes associated with the PE state are enriched for several tissues. 
 
which play important roles in placental development47,54,55. We see a large overlap between FOS 
and JUN predicted target regions, explained by the high similarity in motifs, with almost all JUN 
predicted binding sites in the same region as a FOS predicted binding site [Appendix A: Figure 
3.8]. Therefore, we focus on the MYC, GATA4, and JUN target regions, since JUN has a more 
specific motif than the FOS TF. The genes targeted by MYC and JUN are related to embryonic 
lethality [Figure 3.4b,c] while GATA4 target genes are related to abnormal embryonic size, a 
common effect of abnormal placental development or function56,57 [Figure 3.4d]. 
We identified several placenta specific TFs within this network including PPARG, 
GATA3, CDX2, ATF3, and BHLHA15 [Figure 3.4a -green outline; Figure 3.4e]. PPARG, 
GATA3, and CDX2 are known to be involved in trophoblast differentiation58–61. ATF3 has been 
found to be decreased in preeclamptic placentas in response to hypoxia62.  Interestingly, one of 
these expressed placenta-specific transcription factors, BHLHA15, may have roles in placenta 
that have not been fully elucidated. Therefore, we used the predicted binding sites of BHLHA15 
to analyze the enriched terms associated with its potential target genes and found that BHLHA15 
is associated with genes involved in abnormal placental and labyrinth morphology [Figure 3.4f].   
Discussion  
Using ChIP-seq for several histone modifications, we annotated chromatin states in the 
e9.5 placental genome identifying enhancers and promoters. We also identified a TF network of 
genes enriched within active enhancers that were predicted to target placenta-specific genes, 
some of which have not been well-studied in placental development. While other studies have 
used chromatin modifications to identify regulatory elements in trophoblast stem cells or the  
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Figure 3.4. Transcription factors enriched in active enhancer. (a) TF-network identified by 
STRING containing the enriched TFs within the AE state regions. The darker the color, the 
higher the number of connections (edges). Light green outline indicates a placenta-specific gene 
as defined by TissueEnrich. (b) The MYC TF targets genes associated with embryonic lethality. 
(c) The JUN TF targets genes associated with embryonic lethality and size. (d) The GATA4 TF 
targets genes associated with embryonic size and cell morphology. (e) TissueEnrich heatmap 
showing the expression of placenta specific genes across all analyzed tissues. (f) The BHLHA15 
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e14.5 placenta, this is the most thorough annotation of the e9.5 placenta. This data can be 
adapted to many other analyses. Using our pipeline with ChromHMM and the trophoblast stem 
cell and e14.5 placenta data, we could compare the chromatin landscape throughout development 
to see how regulatory elements change in activity. Our data can also be used to identify possible 
regulatory elements for genes of interest within the placenta or be combined with other datasets 
such as TF ChIP-seq to find whether the TF is associated with active promoters or correlated 
with a specific histone mark.  
However, we recognize certain limitations associated with this study. First, there may be 
problems with our underlying assumptions of histone modifications. Though general rules of 
histone modifications have been established, modifications have been found to break those rules. 
For example, the repressive H3k27me3 mark has been found within promoters of highly 
expressed genes63, and H3k4me3 is generally associated with active transcription, but not all 
genes marked are transcribed64. This is evident when we look at the expression of the AP and PP 
states. Though AP state genes are significantly more highly expressed, there is a wide range in 
expression level and many genes of the PP state are also considered expressed. We also found 
that some states seem to be residual noise from their neighboring, stronger states. For example, 
state 11 shows similar marks as the AP state, without the strong H3k27ac mark. We see that 
about 50% of state 11 regions are within 500bps of an AP state region, potentially indicating 
they are flanking these regions. To further classify and distinguish states to characterize the 
genome, it may be beneficial to profile several other histone modifications such as H3k36me3, 
distinguishing intergenic from intronic enhancers, or H3k9me3 marking constitutive 
heterochromatin. Other datasets can also help annotate cis-regulatory regions – such as RNA 
PolII ChIP to mark sites of active transcription. 
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Interestingly, we found that some states contained conflicting histone marks. For 
example, ChromHMM identified a state (State 12) characterized by the presence of  all four 
histone modifications [Figure 3.1a]. Since several marks are conflicting and not found together 
(H3k4me3/H3k4me1and H3k27ac/H3k27me3), the biological relevance of this finding remains 
to be understood. One possibility is that, since many of these genes play cell-specific roles within 
the placenta, the genes could be active in certain cell types and repressed in other cell types. To 
avoid such issues, future experiments should test a similar protocol on homogeneous populations 
of cells representing the major subtypes within the placenta or using single-cell ChIP-seq. Such 
datasets would be contain less noise due to cellular heterogeneity and provide more robust 
identification of regulatory regions. 
Our analysis also led to the identification of several interesting TFs enriched within 
active enhancers, including BHLHA15 and GATA4. BHLHA15 (MIST1) plays an important 
role in cellular organization of the pancreas65, although gene ontology analyses based on 
predicted targets in the placenta reveal that it may also be involved in placental development. 
GATA4 has not been thoroughly investigated within the context of the placenta, though GATA3, 
a protein with a very similar binding site has been found to be important in trophoblast 
differentiation60, as well as migration and invasion of trophoblast cells66. To validate that 
GATA4 is regulating active enhancers, rather than GATA3, or that BHLHA15 is regulating 
these enhancers, several experiments would be required. ChIP-seq can be used in order to verify 
their binding regions and gene knockout studies are important in order to clarify a role in 
placental development. Luciferase assays would quantify activity levels of predicted repressors 
or activators, or methods such as STARR-seq could be utilized in order to verify enhancer 
activity genome-wide. Not only do enhancers need to be verified but HiC can be used to identify 
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the targets of enhancers genome-wide allowing a more accurate conclusion of the functions 
being affected by each regulatory region.  
In conclusion, we have created a valuable resource to aid researchers in understanding 
this critical point of placental development. Information obtained here will be useful for the 
advancement of research in placental development hopefully aiding in the identification of 
regulatory regions important for proper function.  
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Appendix A. Supplemental Figures 
Figure 3.5. Enrichment of positive controls for each histone-modification ChIP experiment.  
 
Figure 3.6. Promoter analysis. a. Barchart showing that accessible regions identified by ATAC-
seq overlap more with the AP state regions than all other states. b. Barchart showing that 
housekeeping genes are more highly associated with AP regions than other state regions. c. 
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Figure 3.7. Enhancer analysis. a. Genes associated with AE state are enriched for terms related to 
placenta morphology and embryonic lethality. b. Genes assocaited with PE state are enriched for 





Figure 3.8. Venn-diagram showing the number of regions associated the FOS motif (left), the JUN motif 
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Appendix B. Supplemental Tables 
Table 3.1. Primers used for ChIP-qPCR 
Gene Forward Reverse Efficiency 
28S CTGGGTATAGGGGCGAAAGAC GGCCCCAAGACCTCTAATCAT 106% 
B4galt5 ATGTGCAGGTCTGCTATGAAGG AGAGAAGCCCTGTTTGAAAGGA 105% 
Ldha CACTCTTGCAGGGACATCGTG CGGGGCCTTAAATGGAAGCTC 106% 
Gapdh CTGGCACTGCACAAGAAGATG AATGAGAGAGGCCCAGCTACTC 106% 





































Table 3.2. Bowtie2 alignment information for ChIP-seq samples 
Histone modification Length Seq Count Alignment 
H3k4me1 50 bp 19238520.33 98.74% 
H3k4me1 50 bp 15794380.00 98.69% 
H3k4me1 50 bp 16638313.00 98.74% 
H3k4me1 50 bp 16291295.00 98.80% 
H3k4me1 50 bp 11499594.67 98.65% 
H3k4me1 50 bp 17737877.00 98.65% 
H3k4me3 50 bp 22115911.00 98.65% 
H3k4me3 50 bp 15805764.33 98.66% 
H3k4me3 50 bp 12746354.00 98.63% 
H3k4me3 50 bp 24771522.67 98.66% 
H3k4me3 50 bp 21273346.00 98.74% 
H3k4me3 50 bp 21269254.00 98.69% 
H3k27me3 100 bp 40728864.00 98.82% 
H3k27me3 100 bp 42090018.00 98.72% 
H3k27me3 100 bp 48789091.00 98.75% 
H3k27me3 100 bp 57803329.00 98.69% 
H3k27ac 36 bp 32552495.00 97.82% 
H3k27ac 36 bp 35710730.00 98.05% 
Input 100 bp 36587463.00 98.69% 
Input 100 bp 48789220.00 98.80% 
Input 100 bp 48811004.00 98.70% 
Input 100 bp 42794918.00 98.63% 
Input 36 bp 32431185.00 97.97% 
Input 36 bp 20724692.00 96.70% 
Input 50 bp 16209136.33 98.71% 
Input 50 bp 16826296.67 98.69% 
Input 50 bp 17527884.33 98.69% 
Input 50 bp 15378941.33 98.66% 
Input 50 bp 16696087.67 98.72% 
Input 50 bp 17351806.33 97.90% 
Input 50 bp 16630681.33 98.68% 
Input 50 bp 17361979.00 98.72% 
Input 50 bp 9104063.67 98.74% 
Input 50 bp 19050516.33 98.72% 




Table 3.3. Homer known enriched transcription factors 
Motif Name Consensus P-value q-value (Benjamini) 
# of Target 
Sequences 
with Motif 




NPAS NVCACGTG 1.00E-11 0.00E+00 1495 7038.4 Npas2 
Zfp281 CCCCTCCCCCAC 1.00E-11 0.00E+00 311 1150.8  
BORIS CNNBRGCGCCCCCTGSTGGC 1.00E-10 0.00E+00 209 725.9  
Max RCCACGTGGYYN 1.00E-09 0.00E+00 651 2821.1  
MNT DGCACACGTG 1.00E-09 0.00E+00 1010 4639.8  
n-Myc VRCCACGTGG 1.00E-09 0.00E+00 615 2666.1  
BMAL1 GNCACGTG 1.00E-09 0.00E+00 1671 8117.5  
c-Myc VVCCACGTGG 1.00E-08 0.00E+00 498 2107.6  
CTCF AYAGTGCCMYCTRGTGGCCA 1.00E-08 0.00E+00 150 498.4  
Fli1 NRYTTCCGGH 1.00E-08 0.00E+00 864 3958.8  
Rfx5 SCCTAGCAACAG 1.00E-08 0.00E+00 372 1520  
COUP-TFII GKBCARAGGTCA 1.00E-08 0.00E+00 1280 6116.5  
Jun-AP1 GATGASTCATCN 1.00E-08 0.00E+00 208 757.7 Jun 
Etv2 NNAYTTCCTGHN 1.00E-08 0.00E+00 811 3708.6  
ETV4 ACCGGAAGTG 1.00E-07 0.00E+00 852 3946.3  
Elf4 ACTTCCKGKT 1.00E-07 0.00E+00 860 4000.5  
COUP-TFII AGRGGTCA 1.00E-07 0.00E+00 1466 7181.5  
FOXM1 TRTTTACTTW 1.00E-07 0.00E+00 1082 5165.6  
Nrf2 HTGCTGAGTCAT 1.00E-07 0.00E+00 59 152  
Elk1 HACTTCCGGY 1.00E-06 0.00E+00 371 1573.4  
FOXA1 WAAGTAAACA 1.00E-06 0.00E+00 1040 4973.7  
ETS1 ACAGGAAGTG 1.00E-06 0.00E+00 862 4053.8  
ELF1 AVCCGGAAGT 1.00E-06 0.00E+00 352 1484.7  




Table 3.3 Continued 
Motif Name Consensus P-value q-value (Benjamini) 
# of Target 
Sequences 
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THRb TRAGGTCA 1.00E-06 0.00E+00 3659 19143.9  
Cdx2 GYMATAAAAH 1.00E-06 0.00E+00 692 3188.1  
ZNF143|STAF ATTTCCCAGVAKSCY 1.00E-06 0.00E+00 393 1689.7 Znf143 
caudal GGYCATAAAW 1.00E-06 0.00E+00 710 3287.3  
ZFX AGGCCTRG 1.00E-06 0.00E+00 1030 4942.9  
Fosl2 NATGASTCABNN 1.00E-06 0.00E+00 264 1072.3  
Fos NDATGASTCAYN 1.00E-06 0.00E+00 438 1926.5  
Fra2 GGATGACTCATC 1.00E-06 0.00E+00 360 1548.9  
ERG ACAGGAAGTG 1.00E-05 0.00E+00 1353 6672  
EHF AVCAGGAAGT 1.00E-05 0.00E+00 1112 5402.3  
AP-1 VTGACTCATC 1.00E-05 0.00E+00 566 2583.1  
ETV1 AACCGGAAGT 1.00E-05 0.00E+00 1125 5481.6  
Nr5a2 BTCAAGGTCA 1.00E-05 0.00E+00 559 2553.3  
Foxf1 WWATRTAAACAN 1.00E-05 0.00E+00 915 4390  
Ets1-distal MACAGGAAGT 1.00E-05 0.00E+00 292 1229 Ets1 
BATF DATGASTCAT 1.00E-05 0.00E+00 503 2277.4  
GATA1 DDWWYYAGATCTRRW 1.00E-05 0.00E+00 359 1559.8  
GATA3 AGATSTNDNNDSAGATAASN 1.00E-05 0.00E+00 100 339.4  
Maz GGGGGGGG 1.00E-05 1.00E-04 1117 5458.7  
ETS AACCGGAAGT 1.00E-05 1.00E-04 229 933.3  
JunB RATGASTCAT 1.00E-05 1.00E-04 414 1840.2  
NF-E2 GATGACTCAGCA 1.00E-05 1.00E-04 64 193.4  
FOXA1 WAAGTAAACA 1.00E-04 2.00E-04 1203 5964.6  
EWS:ERG-fusion ATTTCCTGTN 1.00E-04 2.00E-04 628 2956.4 EWS 
Atf3 DATGASTCATHN 1.00E-04 3.00E-04 489 2251.7  
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NFE2L2 AWWWTGCTGAGTCAT 1.00E-04 3.00E-04 77 257.8  
Bach2 TGCTGAGTCA 1.00E-04 4.00E-04 165 658.3  
KLF3 NRGCCCCRCCCHBNN 1.00E-04 4.00E-04 374 1682.5  
Usf2 GTCACGTGGT 1.00E-04 4.00E-04 225 946.9  
EAR2 NRBCARRGGTCA 1.00E-04 4.00E-04 1111 5510.3  
ZNF341 GGAACAGCCG 1.00E-04 4.00E-04 625 2964.6  
NeuroD1 GCCATCTGTT 1.00E-04 4.00E-04 699 3350  
GATA4 DDWTYAGATCTR 1.00E-04 4.00E-04 594 2807.4  
ERRg GTGACCTTGRVN 1.00E-04 0.0004 674 3222.3  
SF1 CAAGGHCANV 1.00E-04 0.0004 498 2316.6  
ELF3 ANCAGGAAGT 1.00E-04 0.0006 623 2969.3  
NeuroG2 ACCATCTGTT 1.00E-04 0.0007 1314 6616.6  
CLOCK GHCACGTG 1.00E-04 0.0007 391 1785  
GSC RGGATTAR 1.00E-04 0.0009 1142 5709.5  
Elk4 NRYTTCCGGY 1.00E-04 0.0009 344 1552.7  
HuR BTTTGGTTTG 1.00E-04 0.0009 3643 19342.6  
Nr5a2 BTCAAGGTCA 1.00E-04 0.0009 710 3434.1  
ELF5 ACVAGGAAGT 1.00E-04 0.0009 608 2906.6  
RARa TTGAMCTTTG 1.00E-04 0.001 2606 13636.7  
Ap4 NAHCAGCTGD 1.00E-04 0.001 975 4832.6  
ARE RGRACASNSTGTYCYB 1.00E-04 0.0011 294 1308 AR 
At2g33710 WTKGCGGCKR 1.00E-03 0.0011 666 3214.7  
EWS:FLI1-fusion VACAGGAAAT 1.00E-03 0.0012 455 2126.7  
GATA3 AGATGKDGAGATAAG 1.00E-03 0.0016 79 284  
AP-2alpha ATGCCCTGAGGC 1.00E-03 0.0023 537 2569.7 Tfap2a 
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Bach1 AWWNTGCTGAGTCAT 1.00E-03 0.0035 57 194.5  
Esrrb KTGACCTTGA 1.00E-03 0.0041 547 2639.4  
PPARE TGACCTTTGCCCCA 1.00E-03 0.0042 821 4080.4 Pparg 
PU.1 AGAGGAAGTG 1.00E-03 0.0043 441 2093.4  
BHLHA15 NAMCAGCTGK 1.00E-03 0.0045 1182 6006.5  
PPARa VNAGGKCAAAGGTCA 1.00E-03 0.0046 935 4690.7  
FoxL2 WWTRTAAACAVG 1.00E-03 0.0049 786 3903.8  
Pax7 NTAATTDGCYAATTANNWWD 1.00E-03 0.0049 29 81.3 
 
USF1 SGTCACGTGR 1.00E-03 0.0053 307 1415.2  
HIF-1b RTACGTGC 1.00E-03 0.0053 760 3771.3 Arnt 
HNF4a CARRGKBCAAAGTYCA 1.00E-03 0.0059 433 2064.1  
Reverb GTRGGTCASTGGGTCA 1.00E-03 0.0062 122 501.5 Nr1d1 
TR4 GAGGTCAAAGGTCA 1.00E-03 0.0073 115 470.2  
Arnt:Ahr TBGCACGCAA 1.00E-02 0.0084 408 1946.1 Ahr 
RXR TAGGGCAAAGGTCA 1.00E-02 0.0085 946 4780.7  
ARF2 TTGTCGGMWN 1.00E-02 0.0086 2603 13775.6  
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Abstract 
During pregnancy, the placenta is important for transporting nutrients and waste between 
the maternal and fetal blood supply, secreting hormones, and serving as a protective barrier. To 
better understand placental development, we must understand how placental gene expression is 
regulated. We used RNA-seq data and ChIP-seq data for the enhancer associated mark, H3k27ac, 
to study gene regulation in the mouse placenta at embryonic day (e) 9.5, when the placenta is 
developing a complex network of blood vessels. We identified several upregulated transcription 
factors with enriched binding sites in e9.5-specific enhancers. The most enriched transcription 
factor, PLAGL1 had a predicted motif in 233 regions that were significantly associated with 
vasculature development and response to insulin stimulus genes. We then performed several 
experiments using mouse placenta and a human trophoblast cell line to understand the role of 
PLAGL1 in placental development. In the mouse placenta, Plagl1 is expressed in endothelial 
cells of the labyrinth layer and is differentially expressed in placentas from mice with gestational 
diabetes compared to placentas from control mice in a sex-specific manner. In human trophoblast 
cells, siRNA knockdown significantly decreased expression of genes associated with placental 
vasculature development terms. In a tube assay, decreased PLAGL1 expression led to reduced 
cord formation. These results suggest that Plagl1 regulates overlapping gene networks in 
placental trophoblast and endothelial cells, and may play a critical role in placental development 





The placenta is a specialized organ playing a crucial role in the health of the fetus and 
mother during pregnancy, regulating the exchange of nutrients, gases, hormones and waste[1]. 
Inefficient transfer of materials from the mother to the fetus is frequently associated with adverse 
health outcomes for the fetus[2]. The placenta also plays a protective role, regulating the immune 
response of cells and preventing toxic elements from reaching the fetus[3,4]. Placental 
insufficiency, as well as many other placental abnormalities, have been attributed to misregulated 
gene expression[5,6]. Despite its importance, many aspects of placental development and the 
genetic mechanisms involved in its function remain unknown. 
To elucidate these mechanisms, many researchers utilize the mouse model, which has 
contributed greatly to our understanding of the development of the placenta. Similar to humans, 
rodents have a single disc-shaped, hemochorial placenta[7] to sustain the fetus during 
development. In the human placenta, trophoblast cells invade deeply into the myometrium, and 
partially replace the endothelial wall of maternal spiral arteries, thereby channeling maternal 
blood into the intervillous spaces. Trophoblast lining the villi can then exchange factors between 
the maternal blood and fetal vessels running through the villous core [1]. Similarly, in the mouse, 
trophoblast cells replace the endothelial wall of maternal spiral arteries in the near decidua, 
channeling maternal blood through trophoblast-lined canals to spaces in the labyrinth, which are 
surrounded by trophoblast that exchange material between the maternal blood and the adjacent 
fetal vessels[8]. Labyrinth formation begins around embryonic day (e)8.5 with the fusing of the 
chorion and allantois. Subsequently, the chorion begins to fold and form branches that become 
the trophoblast-lined maternal blood spaces, while allantoic offshoots form the interdigitating 




trophoblasts assuming key endothelial properties, are critical for placental development and 
function. 
Regulation of these complex interactions requires transcriptional machinery to interact 
with the appropriate regulatory elements and cofactors in a spatiotemporal manner. A common 
cause of genetic misregulation is disruption of cis-regulatory elements, specifically in 
enhancers[10,11].  Despite the crucial role enhancers play in gene regulation, there remains a 
large deficit in our understanding of the gene-enhancer regulatory networks that are important 
for placental function [12], including trophoblast-endothelial cell interactions. 
A previous study compared the enhancer landscape before (e7.5) and after (e9.5) 
chorioallantoic fusion in the mouse placenta, identifying an e7.5-specific cell migration network 
of transcription factors (TFs) and enhancers [13]. The goal of the present study is to identify 
e9.5-specific TFs and enhancers critical to placental development. In order to identify novel TFs 
that could be important for regulating processes in the mouse placenta after chorioallantoic 
fusion, we utilized publicly available H3k27ac ChIP-seq data, defining putative active enhancers 
in the e7.5 and e9.5 placenta, as well as RNA-seq data generated at the same timepoints[13]. We 
identified several highly expressed TFs that were upregulated in the e9.5 placenta. One of these 
TFs, pleiomorphic adenoma gene-like 1 (PLAGL1), has a motif highly enriched in e9.5-specific 
enhancers compared to e7.5-specific enhancers. Overexpression of PLAGL1 has been associated 
with transient neonatal diabetes mellitus[14], while reduced expression has been found in female 
intrauterine growth restricted placentas, suggesting it plays an important role[15]. 
To further understand the functions of PLAGL1, we carried out additional experiments in 
mouse placenta and a human trophoblast cell line HTR-8/SVneo, due to the high expression of 




we were able to identify novel functions for PLAGL1 in two models frequently used to study 
human placenta, which could contribute to insights into placental development and certain 
pregnancy disorders. 
Results 
E9.5-specific genes and enhancers are associated with vasculature development 
RNA-seq and H3k27ac ChIP-seq were previously carried out on mouse placenta at e7.5 
and e9.5 to identify genes upregulated and enhancers specific to the e7.5 timepoint [13]. 
However, the genes upregulated at e9.5, as well as the enhancers more active at this timepoint 
were not thoroughly investigated. We first analyzed the 583 genes that were highly expressed 
and upregulated at e9.5 (fragments per kilobase of transcript per million of mapped reads 
(FPKM)³ 10, fold ³2, and FDR £0.05). As expected, we see higher e9.5 expression of genes 
related to processes important in the e9.5 placenta including, Apoa1 (lipid metabolism[16]); 
Notch1, Col1a1, and Dlc1 (blood vessel development[17-19]); Gcm1 (hormone production [20]); 
Igfbp2, Pappa2, Ada (fetal growth and development [21], [22], [23]); and Syna (trophoblast 
differentiation [24]) [Figure 4.1a]. We then used the Genomic Regions Enrichment of 
Annotations Tool (GREAT)[25] to identify the biological processes associated with the highly 
expressed and upregulated e9.5 genes using the single nearest gene option. In general, we found 
that terms related to metabolism and vasculature development are more enriched in genes 




Figure 4.1. Genes and enhancers enriched in the placenta at e9.5 are associated with vasculature 
development. (a) Examples of genes significantly upregulated at e9.5 (FPKM ³ 10, fold ³2, and 
FDR£0.05) that are also associated with placental functions. (b) Top 10 GO biological process 
terms, according to GREAT, using the hypergeometric fold (³2), FDR (£0.05), and gene 
association (³5 associated genes) cutoffs. Genes significantly upregulated at e9.5 are related to 
lipid metabolism, and vasculature development. (c) Examples of e9.5-specific enhancers and 
their corresponding H3k27ac activity at e9.5 and e7.5, shown using the UCSC genome browser. 
Boxes correspond to regions identified as e9.5-specific. (d) E9.5-specific enhancers are 
associated with genes involved in proliferation, response to hormones, and placenta vasculature 
development. 
 
Next, we analyzed e9.5-specific enhancers. We observed that e9.5-specific enhancers 
were located near genes with known roles in the midgestation placenta [Figure 4.1c]. For 
example, Notch1 plays a role in promoting trophoblast differentiation, and regulates 
angiogenesis and placental branching[17,26]. Dlc1, a tumor suppressing gene, also contributes to 
the development of placental vasculature[27]. Ontology analysis of the e9.5-specific enhancers 
showed that many terms, such as ‘response to insulin stimulus’ and ‘abnormal placental 
vasculature’, are more significantly enriched in e9.5-specific enhancers compared to e7.5-




Since both upregulated genes and enhancers specific to e9.5 were associated with 
placental development terms, such as vasculature and labyrinth morphology, we next 
investigated which TFs could be regulating these processes. 
Plagl1 is highly expressed in the e9.5 placenta and the PLAGL1 binding motif is enriched 
in e9.5-specific enhancer regions 
To identify TFs that could be regulating e9.5-specific enhancers, we first determined 
which ones were upregulated at e9.5. Based on expression thresholds (FPKM ³ 10), fold (³2), 
and q-value (£0.05), we identified 37 TFs upregulated at e9.5 [Figure 4.2a; Appendix B: Figure 
4.7; Appendix C: Table 4.2]. We then used a phylofootprinting approach[28] to determine which 
of these TFs had motifs enriched in e9.5-specific enhancers. We ensured that the binding site 
predictions were conserved between the human and mouse genome since conserved binding sites 
are more likely to be functionally important[29]. Four TFs passed our motif fold (³1.5) and p-
value (£ 0.05; Bonferonni correction) cutoffs: PLAGL1, GCM1, PPARg, and BHLHB2 [Figure 
4.2b]. Interestingly, each of these TFs has a known role in the placenta, though some TFs are 
better studied. GCM1 is a well-known, important transcription factor expressed within 
labyrinthine trophoblast[30] that contributes to syncytiotrophoblast differentiation, chorionic 
branching[31], and hormone production[20]. PPARg is also well-studied, known to play a variety 
of roles in the placenta including fatty acid uptake, differentiation, and vascularization[32-34]. 






Figure 4.2. The PLAGL1 motif is enriched in e9.5-specific enhancers and is associated with 
blood vessel development genes. (a) Scatterplot showing the expression of all TFs at e7.5 and 
e9.5. Upregulated TFs at e9.5 are indicated by maroon triangles (fold ³ 2, and p-value £ 0.05). 
(b) Of the 37 transcription factors upregulated at e9.5, four TFs (maroon triangles) pass the 
fold and Bonferroni corrected p-value thresholds (black lines).  
PLAGL1 had a high expression fold change (fold change: 46.93; e7.5 FPKM: 0.99; e9.5 
FPKM 45.26) as well as the highest, most significant fold change among binding sites of the four 
TFs [Figure 4.2b].  PLAGL1, is an imprinted zinc-finger transcription factor known to play roles 
in regulating glucose uptake[36], apoptosis[37], and proliferation[38] and peaks in expression in 
the midgestation human placenta[39]. Although several functions of PLAGL1 have been 
identified, its role in placenta has not been thoroughly studied. Therefore, we performed 
additional experiments in both the mouse placenta as well as human trophoblast cells. 
Plagl1 is expressed in endothelial cells of the labyrinthine layer  
To determine where within the mouse placenta Plagl1 is expressed we performed 
RNAscope with an e9.5 implantation site. Plagl1 expression was observed within the developing 
labyrinth; specifically, in the endothelial cells forming the fetal blood vessels [Figure 4.3a, 
Appendix B: Figure 4.8a]. Positive (PPIB) and negative(DapB) control probes were used for 
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Appendix B: Figure 4.8b-c]. Immunohistochemistry for CD34, a marker for vascular endothelial 
cells[40,41], was also performed and showed a similar staining within the labyrinth [Figure 4.3d; 
Appendix B: Figure 4.8d]. Plagl1 is also expressed throughout the allantois, where fetal 
vasculature begins developing, eventually forming the endothelia in the labyrinth layer of the 
placenta[42], suggesting a role for PLAGL1 in vasculogenesis and labyrinth layer morphology.  
Plagl1 is associated with blood vessel development and insulin response 
The PLAGL1 motif was identified in 233 e9.5-specific enhancers that were predicted to 
associate with genes involved in fetal growth, placental labyrinth morphology, and insulin 
response [Figure 4.4a]. These enhancers were also predicted to associate with genes involved in 
obesity and overnutrition [Figure 4.4a]. Interestingly, maternal gestational diabetes mellitus 
(GDM) has been associated with defective insulin signaling within the placenta[43] and 
increased vascularization[44],  leading us to hypothesize that Plagl1 could be misexpressed in 
GDM placentas. To determine if Plagl1 expression differs between control placentas and those 
from GDM mothers, we measured its gene expression in placentas from a mouse model for 
GDM[45]. Mice were fed a high-fat, high-sucrose diet a week prior to mating and throughout 
pregnancy resulting in glucose intolerance during pregnancy[45]. When comparing placentas 
from control mice and placentas from GDM mice at e17.5, we observed no significant difference 
in Plagl1 expression(p-value=0.07). Since the placental environment has been shown to affect 
males and females differently[46,47], and PLAGL1 has also been shown to have sex-specific 







Figure 4.3. Plagl1 is expressed within the developing labyrinth layer and allantois of the e9.5 
mouse placenta. (a) RNAscope shows Plagl1 RNA in the developing labyrinth as well as 
throughout the allantois (dark red) in the e9.5 placenta. Box shows zoomed in region (right). 
Arrowheads indicate Plagl1 staining of endothelial cells forming fetal blood vessels. (b) 
RNAscope positive control staining PPIB within the placenta to determine RNA viability. (c) 
RNAscope negative control staining DapB within the placenta to determine nonspecific staining. 
(d) Immunohistochemistry shows CD34 staining of the vascular endothelial cells, displaying a 
similar pattern to Plagl1 within the developing labyrinth. Box shows zoomed in region (right). 















































First, we compared Plagl1 gene expression in control female placentas and control male 
placentas and found no difference (p-value=0.98). Then, after normalizing Plagl1 expression in 
GDM placentas to control placentas for each sex, we found significant upregulation of Plagl1 in 
the GDM placentas in males only (p-value=0.031) [Figure 4.4b; Appendix C: Table 4.3]. These 
findings indicate that GDM affects Plagl1 in the placenta in a sex-specific manner in a murine 
model of GDM.  
Figure 4.4. PLAGL1 is associated with placental morphology and Plagl1 shows sex-specific 
differences in GDM mouse placentas. (a) The 233 e9.5-specific enhancers containing a PLAGL1 
motif are associated with fetal growth, vasculature development, and other processes important 
in the placenta. (b) Plagl1 is significantly overexpressed in the male placenta from mothers 
modeling GDM, but not in female placentas (p-value £ 0.05(*)). 
 
PLAGL1 knockdown in the HTR-8/SVneo cell line predicts a role in blood vessel 
remodeling 
We next investigated a potential role for PLAGL1 in human placenta. Using data from 
the human protein atlas[48] and the TissueEnrich tool[49], we found that PLAGL1 has placenta-




sections used for analysis were comprised primarily of trophoblast cells [Figure 4.5b]. Therefore, 
we sought to investigate the role of PLAGL1 in human trophoblast cells. First, we evaluated 
RNA-seq data from several human cell lines[50] for PLAGL1 expression, including: 
choriocarcinomas representing villous trophoblast (BeWo[51] and JEG3[52]); 
syncytiotrophoblast (PHTd_Syncytio[53]) differentiated from term placenta cytotrophoblast 
(PHTu_Cyto[53]); BAP treated human embryonic stem cells (ESCd[53]); and a cell line derived 
from chorionic villi explants of first trimester placenta (HTR-8/SVneo[54]). We proceeded with 
our experiments in HTR-8/SVneo cells, since they had the highest expression of PLAGL1 
[Figure 4.5c]. When grown on Matrigel, HTR-8/SVneo cells express genes associated with blood 
vessel development, can form endothelial tube-like structures, and are commonly used to model 
endovascular differentiation of extravillous trophoblast[55-59]. 
To understand the global impacts PLAGL1 has on gene expression, we performed an 
siRNA knockdown of PLAGL1 followed by RNA-seq in the HTR-8/SVneo cells. We first tested 
two siRNAs, and found that both siRNAs knocked down PLAGL1 by 73-75% on average 
[Figure 4.5d]. Since both siRNAs showed similar knockdown efficiencies, we proceeded with 
RNA-seq using siRNA 1. We identified 4,003 genes that were differentially expressed (fold ≥ 
1.5, adjusted p-value ≤ 0.05) between the PLAGL1 and negative control knockdown samples 
using DESeq2[60] [Figure 4.5e]. The 1,964 genes that were increased upon PLAGL1 knockdown 
included several protocadherins such as PCDH1, PCDH10, and PCDH7. The only terms 
enriched in this group were related to cell-cell adhesion [Figure 4.5f]. On the other hand, the 




blood vessel development, cell migration, and both type 1 (insulin dependent) and type 2 (non-
insulin dependent) diabetes [Figure 4.5g; Appendix B: Figure 4.9]. 
Figure 4.5. PLAGL1 regulates genes involved in blood vessel development. (a) Bar graph of 
PLAGL1 expression in human tissues, generated using TissueEnrich. Expression reported using 
transcripts per million (TPM). (b) Percentage of trophoblast and endothelial cells in human 
placental samples. Data is from the Human Protein Atlas. (c) Bar graph of PLAGL1 expression 
in multiple human cell lines. (d) PLAGL1 expression is significantly reduced by two siRNAs (p-
value<=0.01 (**)) compared to a negative control. Values are normalized to the negative control 




cells. Genes which increase (1,964) in expression are indicated as orange dots on the volcano 
plot and those that decrease (2,039) are purple. (f) Cell-adhesion terms are associated with genes 
that are upregulated when PLAGL1 is knocked down. (g) Vasculature development terms are 
associated with genes that are downregulated when PLAGL1 is knocked down. 
 
To determine if PLAGL1 could play a role in the ability of HTR-8/SVneo cells to mimic 
endothelial cell tube-like structure formation, we performed a tube formation assay. Ten hours 
after plating the cells transfected with the PLAGL1 siRNA, we see a significant decrease in cord 
formation, as determined by the total branching length (p-value=0.0093) and number of enclosed 
regions (meshes; p-value=0.0024) compared to cells transfected with a negative control [Figure 
4.6]. 
Figure 4.6. PLAGL1 knockdown decreases cord formation ability in HTR-8/SVneo cells. (a) 
Representative images showing cord formation is reduced after PLAGL1 is knocked down (left) 
compared to a control (right). (b) Branch length was significantly reduced after PLAGL1 
knockdown (p-value £ 0.01(**)). (c) Enclosed regions, or meshes, were significantly reduced 





Relationship between mouse and human Plagl1 results  
The gene networks regulated by PLAGL1 in mouse placenta, where it is expressed by 
endothelial cells, and in HTR-8/SVneo human trophoblasts are, at least partially, conserved. For 
example the GO terms enriched for genes downregulated upon PLAGL1 knockdown in HTR-
8/SVneo cells were similar to the terms associated with the genes we initially predicted to 
contain PLAGL1-binding motifs in their enhancer regions in the mouse genome (Figure 4.4a, 
Figure 4.5g). Therefore, we tested whether the specific genes associated with terms enriched for 
predicted PLAGL1 enhancers decreased in expression after PLAGL1 was knocked down in 
HTR-8/SVneo cells. To do this, we focused on the terms that were associated with PLAGL1 
enhancers – ‘abnormal placental labyrinth vasculature morphology’, ‘regulation of cellular 
response to insulin stimulus’, and ‘placental development’. Of the eight target genes associated 
with ‘abnormal placental labyrinth vasculature morphology’, four were downregulated upon 
PLAGL1 knockdown in HTR-8/SVneo cells (p-value of overlap=0.00188). Of the five predicted 
PLAGL1 target genes associated with ‘regulation of cellular response to insulin stimulus’, three 
were downregulated upon PLAGL1 knockdown in HTR-8/SVneo cells (p-value of 
overlap=0.00161). Of the 11 predicted PLAGL1 target genes associated with the more general 
term, ‘placental development’, five were downregulated upon PLAGL1 knockdown (p-value of 
overlap=0.00159) [Appendix B:  Figure 4.10a].  
We further determined if the enhancers identified in mouse could drive gene activity in 
the HTR-8/SVneo cells. We performed a dual-glow luciferase assay using five enhancers 
predicted to be bound by PLAGL1 and target genes with varying functions, including blood 
vessel development (COL1A1[18]), migration (DLC1[61]), signal transduction 




all of these regions were indeed acting as enhancers within the HTR-8/SVneo cells (relative 
luciferase activity ³ 2) [Appendix B: Figure 4.10b]. To confirm PLAGL1 regulates the activity 
of these enhancers, we tested the activity with and without an siRNA-mediated knockdown. 
After PLAGL1 knockdown, the enhancer activity significantly decreased in three out of five of 
these enhancers [Appendix B: Figure 4.10c]. 
Discussion 
By combining RNA-seq and ChIP-seq data from the mouse placenta, we identified 
Plagl1 as an upregulated transcription factor that has its motif enriched within e9.5-specific 
enhancers. In mouse, gene ontology analysis showed that PLAGL1 was predicted to associate 
with genes involved in labyrinth layer development and fetal growth. Plagl1 was expressed 
throughout the allantois and within vascular endothelial cells of the labyrinth layer. We also 
found that Plagl1 has sex-specific gene expression differences between normal placentas and 
those from the GDM mouse model. Next, we performed an siRNA-mediated knockdown of 
PLAGL1 in HTR-8/SVneo cells to determine if the gene could be important in human placental 
trophoblast cells. Ontology analysis of genes which decreased in expression upon PLAGL1 
knockdown showed enrichment of terms related to blood vessel remodeling. PLAGL1 was 
further implicated in this role by a tube formation assay, where we observed a decrease in cord 
formation in PLAGL1 knockdown cells.       
In mouse, the importance of PLAGL1 in fetal growth has been established, as pups from 
global PLAGL1 knockout mice are smaller in size compared to wild type pups. The authors 
found a slight decrease in placental weight by gestational day 16.5. However, they did not report 
a difference in the histology of the placenta or its ability to transport glucose[65]. Our analysis 




genes are associated with ‘regulation of cellular response to insulin stimulus’ and ‘abnormal 
placental labyrinth vasculature morphology’ [Appendix B: Figure 4.10a]. These genes were also 
found to significantly decrease in HTR-8/SVneo cells after PLAGL1 knockdown and are a part 
of terms like ‘blood vessel development’. Interestingly, PLAGL1 has been associated with the 
upregulation of each of these genes in beta cell proliferation, and insulin secretion or signaling, 
and both genes have been suggested as targets of study to better understand the role of PLAGL1 
in transient neonatal diabetes[66]. However, such a relationship has not been established in 
placental vasculature although PPARg null placentas, and SOCS3 null placentas both show 
defects in labyrinth formation and maternal blood sinuses[67,68]. Although we predict other 
targets of PLAGL1 that may be involved in blood vessel formation, future work, including 
PLAGL1 ChIP-seq, is necessary to confirm predicted, and identify novel, PLAGL1 binding sites. 
Given the association between PLAGL1 and angiogenic gene expression in the mouse placenta 
prior to major endovascular invasion, a role in blood vessel formation within the labyrinth layer 
is also possible. To test this, placenta-specific knockout of PLAGL1 would need to be generated, 
since Plagl1 is highly expressed in other mouse embryonic tissues, including the liver and 
limb[69]. 
Our findings also revealed that, amongst male placentas, Plagl1 is more highly expressed 
in a mouse model of GDM compared to controls. This adds to the evidence that Plagl1 
methylation and expression are sensitive to the maternal environment. Plagl1 is hypomethylated 
and its expression is upregulated in mouse offspring generated by assisted reproductive 
technologies, and its methylation is associated with maternal folate concentrations, a 
Mediterranean diet, alcohol, and vitamin B2 consumption in women[70-73]. These Plagl1 




of the mouse model of GDM utilized here have greater adiposity, and are more sensitive to 
metabolic disruption of their reproductive systems[75-77]. However, it is not clear whether 
placental Plagl1 plays a functional role in these offspring outcomes, or is simply a marker for 
them; it is a putative metastable epiallele, meaning that environmental alterations in placental 
gene regulation may be maintained in offspring tissues and affect their adult functions[74]. 
Plagl1 knockdown in the human trophoblast cells shows altered expression of Oas1 and Polr2g, 
which are misexpressed in placentas from women with GDM, in the direction that would be 
predicted by PLAGL1 overexpression (downregulated and upregulated, respectively), suggesting 
a functional role for PLAGL1 in GDM-induced placental dysfunction[78]. Moreover, the 
findings here suggest that Plagl1 misexpression could contribute to offspring outcomes in GDM 
by directly regulating placental function. For example, placental capillary density is increased, 
and branching decreased, in placentas from GDM pregnancies[44], consistent with the potential 
role of Plagl1 in angiogenesis that we have uncovered. However, further experiments are needed 
to directly test whether placental angiogenesis is altered in this murine model of GDM, and 
whether Plagl1 is responsible.  
Notably, the effect of GDM on placental Plagl1 expression in this model is sex-specific 
occurring in males only. In contrast, low birthweight is only associated with Plagl1 methylation 
changes in female placentas[74]. Other genes have also been shown to be differentially 
expressed between male and female placentas associated with GDM, including lipolipase, which 
is involved in fatty acid transport and uptake[79]. Interestingly, GDM, like PLAGL1, is known 
to have sex-specific attributes. GDM is more common in pregnancies with a male fetus[80] and 
is also a risk factor for later type 2 diabetes of the fetus, with males developing it more than 




within the placenta for male and female placentas[82], and affect glucose utilization differently 
between the sexes [100]. The mouse model of GDM used here affects the metabolism of both 
male and female offspring, but more dramatically impacts adipose tissue gene expression and 
substrate utilization in males[76]. 
The HTR-8/SVneo cells used for knockdown and subsequent experiments were of female 
origin[83]. Due to the sex-specific responses and expression of Plagl1, it would be advantageous 
to check the results in a male cell line to determine if PLAGL1 regulates the same genes in both 
genders. Much work remains in understanding the impact of sex on PLAGL1 functions and 
regulation.  
Not only can PLAGL1 have sex-specific roles, but PLAGL1 is known to have different, 
or even opposite, functions depending on the type of cells being studied and on the co-factors 
that are expressed with it. For example, PLAGL1 induces activation of the PAC1 receptor 
promoter, unless co-transfected with ERA, which then leads it to repress promoter activity[37]. 
PLAGL1 expression has also been found to be increased in some tumor tissues[84,85], and 
decreased in others[86,87]. Since PLAGL1 can have different effects in different environments, 
it would be interesting to compare the effects of PLAGL1 knockdown in specific subsets of 
trophoblast cells. Recently, human placental cells were cultured and differentiated into 
extravillous and syncytiotrophoblast cells[88], which have varying degrees of PLAGL1 
expression. Knockdown and functional assays on multiple trophoblast subtypes will give us a 
greater insight into the diverse functions and cell-specific roles of PLAGL1. Other cell lines that 
could also be more appropriate for studying aspects of blood vessel formation, and that could 
help better understand the results we observe in mouse, include human placental vascular 




In HTR-8/SVneo cells, we found that genes downregulated upon PLAGL1 knockdown 
were strongly enriched for blood vessel development terms. Interestingly, both HTR-8/SVneo 
cells and primary first trimester trophoblast, but not third trimester trophoblast, are capable of 
cord formation[89], indicating that this property is characteristic of trophoblast cells capable of 
endovascular invasion. We found that by knocking down PLAGL1, cord formation of HTR-
8/SVneo cells was hindered. However, to determine if PLAGL1 has a role in tube formation, 
other methods such as co-culture assays would need to be assessed, since several non-endothelial 
cells can also form tubes in the presence of Matrigel[90]. Genes upregulated upon PLAGL1 
knockdown were enriched for cell adhesion terms. Previous research has found that PLAGL1 
targets genes involved in cellular adhesion and extracellular matrix composition[91,92]. We also 
observed that several immune genes were upregulated including interferons (IRF6, IRF7)[93,94], 
TGFB3[95], and HLA-DQB1[96]. However, the role of PLAGL1 in immunity is unknown. 
Further analysis could reveal a role of PLAGL1 in regulating an immune response in the 
placenta.  
Although we performed experiments and bioinformatics analysis in both mouse placenta 
and a human trophoblast cell line that represent different aspects of trophoblast-endothelial 
interactions in placental development, we do observe similarity of PLAGL1 targets and predicted 
functions, as noted above. In mouse, however, we observed Plagl1 expression in endothelial 
cells, whereas in human we investigated trophoblast cells. It is possible PLAGL1 has a role in 
both cell types in both species, and we could not capture this with the specific timepoint we 
investigated in mouse, and the specific cell line we used in human. We note, however that there 
are also similarities in the genes identified in our study and PLAGL1 target genes identified in 




and checked if they displayed significantly different expression in the embryonic liver (e18.5) of 
WT mice compared to the liver in Plagl1 knockout mice[65]. Of these 15 imprinted genes, we 
found that CDKN1C, DCN, GATM, GRB10, MEG3, and MEST were upregulated in the HTR-
8/SVneo PLAGL1 knockdown cells, while others, including SLC38A4,  IGF2, and IGF2R have 
downregulated family members in the HTR-8/SVneo cells. We found other known imprinted 
targets of PLAGL1 to be disrupted in the HTR-8/SVneo PLAGL1 knockdown cells, such as 
RASGRF1[97]. TP73 and WT1, which were also misregulated upon PLAGL1 knockdown, were 
previously found to be highly methylated in prostate cancer, along with PLAGL1[98].  
Although many roles of PLAGL1 have been well studied in different tissues and cells, 
including its ability to regulate migration[99] in neurons and proliferation[38] in several tissues, 
a role in the placenta has not been thoroughly described. We provide evidence that PLAGL1 
alters angiogenic gene expression and function. Proper remodeling of maternal blood vessels and 
formation of fetal blood vessels are critical for efficient transport of nutrients and oxygen 
between the maternal and fetal blood supply. Errors in this process could lead to several 
complications. Therefore, PLAGL1 may be an interesting target of analysis when understanding 
the pathogenesis of pregnancy diseases.  
Materials and Methods 
Filtering of e7.5 and e9.5 placenta RNA-seq data 
We obtained previously analyzed and published e7.5 and e9.5 placenta RNA-seq data 
from the Gene Expression Omnibus (GSE65808)[13]. TFs were identified from the Animal 
Transcription Factor Database(v2.0)[100]. TFs were considered highly expressed and retained 
for analysis if they had an FPKM ³ 10 at e9.5 and were significantly upregulated compared to 




Binding site predictions 
To identify the potential binding sites of the highly expressed TFs, we used a curated 
library of position weight matrices as previously described[28], only retaining those with high 
information content (³ 10). Using the PRISM phylofootprinting method[28], we predicted 
binding sites for the highly expressed TFs in previously defined e9.5-specific enhancers, 
downloaded from the Gene Expression Omnibus (GSE65807)[13]. We filtered the predictions 
using the parameters as described in [101], only keeping significant (p-value £0.05) predictions 
with a match threshold of at least 0.8 that are conserved in the human genome (hg19). 
Motifs with a similarity threshold of 0.8 were grouped, and only the motif with the 
highest number of occurrences was kept for further analysis. We determined the number of e7.5 
and e9.5 enhancers with each motif and then calculated the fold by determining the proportion of 
enhancers containing a particular motif at e9.5 divided by the proportion at e7.5. Significance 
was determined using the hypergeometric test with Bonferroni correction for multiple 
comparisons. 
RNA-Scope 
RNAscope was performed by the Comparative Pathology Core at Iowa State University 
College of Veterinary Medicine using the RNAscope 2.5 High Definition (HD)-Red Assay 
(Advanced Cell Diagnostics Cat #322350) according to manufacturer’s instructions. Briefly, for 
each biological replicate, e9.5 implantation sites were microdissected from timed-pregnant CD-1 
mice obtained from Charles Rivers Labs. All animal experiments were approved by the Iowa 
State University Institutional Animal Care and Use Committee (Protocol IACUC-18-350) and 
conformed to the NIH Guidelines for the Care and Use of Laboratory Animals.  Each 




deparaffinized and treated with hydrogen peroxide prior to target retrieval, and then treated with 
protease plus. Mm-Plagl1 (cat # 462941) and control probes were applied to slides for 
hybridization followed by six rounds of amplification. The signal was detected with Fast RED 
and slides were counterstained with hematoxylin.  Plagl1 signal appears as red on the slide. 
Control slides included positive control probe Pentidylpropyl isomerase B (Mm-PPIB cat # 
313911) used to determine RNA viability in the samples, and negative control probe DapB (cat # 
310043) to detect nonspecific staining. 
Immunohistochemistry staining 
Paraffin embedded tissue sections, collected as described in the RNA-scope methods 
section, were incubated at 60°C for 20 min. Immediately after incubation, the sections were 
deparaffinized with three washes in xylene for 5 min each, followed by three washes in 100% 
ethanol for 3 min each, one wash in 95% ethanol for 1 min and rinsing the slide under running 
deionized water (DI) for 3 min. Antigen retrieval was achieved by placing the slides in sodium 
citrate buffer (pH 6) for 40 min at 100°C in a water bath. The slides, along with sodium citrate 
buffer were allowed to cool down to room temperature (RT) for 30 min and washed two times in 
PBST buffer (0.1% tween20 in PBS pH 7.4) for 5 min each wash. The sections were blocked 
with hydrogen peroxide (Fisher scientific NC0185217) for 10 min and washed two times with 
PBST buffer, 5 min each. The sections were incubated at RT for 1 hour in blocking buffer (1% 
DMSO and 1% BSA in PBS buffer). After draining the blocking buffer, primary staining was 
performed using the CD34 antibody (Abcam ab81289) at a 1:400 dilution in blocking buffer, and 
slides with primary antibody were incubated overnight at 4°C in a humidified chamber. 
Following primary antibody staining, the sections were washed in six changes of PBST for 5 min 
each and incubated for 1 hour at RT in secondary Goat anti-rabbit HRP antibody (Abcam 




5 min each. The staining was visualized using DAB for 10 min (Fisher scientific NC9276270) 
following the vendors recommended protocol and washing away excess DAB under running DI 
water for 5 min. The sections were counter stained with Mayer’s Hematoxylin (Fisher scientific 
5031794) for 7 min at RT and incubated in bluing agent (Fisher scientific 22050114) for 2 min. 
The sections were washed in DI water and patted dry before mounting.  
GDM placenta qPCR 
All animal procedures were approved by the Baylor College of Medicine institutional 
animal care and use committee and performed in accordance with NIH Guide for the Care and 
Use of Laboratory Animals. Seven week old C57BL/6J female mice were placed on either a 10% 
kcal/fat, 0% kcal/sucrose control diet (Ctrl) or a 45% kcal/fat, 17% kcal/sucrose diet (GDM) one 
week prior to and throughout pregnancy to induce GDM like symptoms as previously 
described[45]. All females were placed with a proven breeder male for one night and then 
examined for copulatory plugs in the morning. Plug positive females were considered pregnant 
and morning of plug positive was designated as day 0.5 of pregnancy. At embryonic day 17.5, 
dams were euthanized. For GDM mice, 10 placentas were dissected from 5 dams. For control 
mice, 11 placentas were dissected from 6 dams. Placenta were individually flash frozen. Flash 
frozen placenta were thawed overnight in RNAlater-ICE and RNA extracted using PureLink 
RNA Mini Kit. Quality of RNA was checked on a 1% Agarose gel. RNA was converted to 
cDNA using the High-Capacity cDNA Reverse transcription Kit (ThermoFisher Scientific 
4368814). Primers used for Plagl1 and Polr2a (mouse) can be found in Appendix C: Table 4.5.  
Sex of the placenta was determined as previously described[102] using PCR to amplify 
either Rbm31x and Rbm31y. Samples were then run on a 1% agarose gel to determine sex 




4.6. TissueEnrich analysis 
PLAGL1 expression data for human tissues was obtained from the ‘Tissue-specific 
Genes’ option of the TissueEnrich[49] webtool. Expression values were based on data from the 
Human Protein Atlas. 
Human Protein Atlas placenta analysis 
To obtain the percentage of trophoblast and endothelial cells in human placenta samples 
used for experiments, we used the eight available samples (sample IDS: 200, 202, 203, 204, 375, 
385, 398, 413) from the Human Protein Atlas[48]. Cell percentages were averaged across 
samples. 
siRNA knockdown and qPCR 
HTR-8/SVneo (ATCC® CRL3271™) cells were cultured in RPMI-1640 (ATCC 30-
2001) with 5% FBS. Cells were seeded at 15 × 104 cells/well in a 6-well plate and grown for 48 
hours before transfecting. Transfections were carried out with the Lipofectamine RNAiMAX 
Transfection Reagent (Fisher Scientific 13778150) and with PLAGL1 siRNA(ThermoFisher 
Scientific 4392420) or a negative control (ThermoFisher Scientific 4390843). We performed a 
media change 24 hours after transfection. RNA was extracted 48 hours after transfection using 
the Qiagen Mini RNA kit and quality was determined using the Bioanalyzer Total RNA nano 
analysis kit (Agilent) and all RNA Integrity Numbers were greater than 8. Concentrations were 
determined using the Nanodrop and 1000ng of RNA from eight biological replicates was 
collected for RNA-seq. 400ng of RNA was then converted to cDNA using the High-Capacity 
cDNA Reverse transcription kit (ThermoFisher Scientific 4368814). PLAGL1 knockdown was 
quantified by Real-Time qPCR. GAPDH was used for normalization and percent knockdown of 
PLAGL1 was calculated using the ∆∆CT method. Primer sequences and efficiency values can be 





Libraries were prepared for all eight replicates by the Iowa State DNA facility using the 
NEBNext Ultra II Directional library prep kit, unique dual index plate, and poly(A) mRNA 
magnetic isolation module, following manufacturer’s protocol. Samples were run on the HiSeq 
3000, across three lanes using single-end 50bp reads. Reads were combined across lanes, aligned 
to the hg19 genome using HISAT2[103](v2.1.0; default parameters) [Appendix C: Table 4.5], 
and transcript abundance was calculated using htseq-count from the HTseq[104] package. 
Significantly differentially expressed genes were identified using DESeq2[60] (1.28.1, default 
parameters) and defined as genes with a fold of at least 1.5 and FDR £ 0.05. All raw and 
processed RNA-seq data have been made available in the GEO repository, under the data 
accession GSE154577. 
Tube formation assay 
Tube formation assays were performed as previously described with minor 
modifications[105]. 150µl of Matrigel (Fisher Scientific CB40234A) was used to coat wells of a 
24-well plate and solidified at 37°C for 1-2 hours. Cells were seeded at a density of 75,000 
cells/well in RPMI-1640 media, 48 hours after treatment with the PLAGL1 siRNA or a 
scrambled control. Images were taken after 10 hours of incubation on the Matrigel using light 
microscopy from three random fields of each well. Cord formation ability was calculated by 
counting the number of meshes and the total branch length using the Angiogenesis Analyzer 
plugin from ImageJ. 
Cloning 
Primers to amplify putative PLAGL1 enhancer regions were designed using the mm9 




previously described[106] with a modification. Target enhancer regions were amplified with 
NEB Q5 DNA polymerase (NEB M0491S) using primers listed in Appendix C: Table 4.6. For 
each enhancer target, three colonies were selected to identify positive clones by colony PCR and 
sequenced with Applied Biosystems 3730xl DNA Analyzer (DNA Facility, Iowa State 
University). 
Enhancer testing with a dual glow luciferase assay 
HTR-8/SVneo cells were seeded at 50,000 cells/well and grown for 24 hours on a 24-
well plate before being transfected with PLAGL1 or the negative control siRNA. 24 hours after 
this, cells were transfected again using Jetprime reagent (VWR 89129-924) with a control 
plasmid or an enhancer cloned into the PGL4.23 vector.  The following day the plates were read 
following the manufacturer’s protocol for the Dual-glow Luciferase Assay kit (Fisher Scientific 
PRE2920). To determine the significance of the relative luciferase assay change, firefly 
luciferase values were normalized to renilla luciferase values and then the knockdown was 
compared to negative control values for the same replicate using a t-test. Experiments were run 
with four biological replicates for siRNA 1. 
Ontology analysis 
Gene ontology enrichment analysis for enhancers was carried out using GREAT 
(v3.0.0)[25] with the GO biological process, mouse phenotype, and disease ontologies. Default 
parameters were used for region-gene associations, unless otherwise specified, and all analyses 
show top terms, ranked by FDR. Ontology enrichment for sets of genes was carried out using 
WebGestalt using over-representation analysis and the biological process database, unless 
otherwise specified. The reference set for comparison was the protein-coding genome and other 





Experiments were repeated in triplicate and results are displayed as the mean ± SE unless 
otherwise indicated. P-values were calculated using student’s t-test unless otherwise specified. 
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Figure 4.7. Transcription factor analysis. Diagram depicting the number of genes remaining after 



















Figure 4.8. RNAscope showing Plagl1 expression in the allantois and labyrinth. (a) Second 
biological replicate of RNAscope showing Plagl1 RNA expression in developing labyrinth and 
the allantois (dark red) of the e9.5 placenta. Box shows zoomed in region (right) and arrowheads 
indicate Plagl1 staining of endothelial cells. (b) RNAscope positive control staining of PPIB. (c) 
RNAscope negative control staining DapB. (d) Second replicate of immunohistochemistry 
showing CD34 staining the vascular endothelial cells. Box shows zoomed in region (right) and 
































































Figure 4.9. Disease ontology for downregulated genes. Disease Ontology terms associated with 
genes that decrease in expression when PLAGL1 is knocked down. 
Figure 4.10. PLAGL1 target gene and enhancer activity. (a) Gene information for three enriched 
terms associated with e9.5-specific enhancers containing a PLAGL1 binding motif. All genes 
listed in the column are a part of the term below it. Genes that are associated with e9.5-specific 
enhancers containing a PLAGL1 binding site that are also downregulated in HTR-8/SVneo cells 
upon PLAGL1 knockdown are in white text (dark purple bar). Genes that are associated with 
e9.5-specific enhancers containing a PLAGL1 binding site that are not downregulated in HTR-
8/SVneo cells upon PLAGL1 knockdown are in black text (light purple bar). (b) Bar graph of 
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active enhancers (relative luciferase activity ³ 2 (black line)). (c) Bar graph of luciferase activity 
for enhancers from (b) with and without a PLAGL1 knockdown. Several enhancers show a 








Appendix C. Supplemental Tables 
Table 4.1. E9.5-specific enhancer gene ontology terms 
This table contains the top 20 gene ontology terms associated with the e9.5-specific enhancers. The bolded terms are 
shown in figure 1. 
  
Go Biological Process 
   
Term Name   Binom 
Rank  
 Binom Raw 
P-Value  
  Binom FDR Q-
Val   
 Binom Fold 
Enrichment  
 Binom Observed 
Region Hits  
 Binom Region 
Set Coverage  
placenta development 48 4.68E-20 9.81E-18 3.08 91 0.043 
actin cytoskeleton organization 59 2.63E-16 4.48E-14 2.21 130 0.061 
actin filament-based process 62 2.80E-15 4.55E-13 2.11 134 0.063 
actin filament organization 71 2.16E-12 3.05E-10 2.80 62 0.029 
posttranscriptional regulation of gene expression 77 5.19E-12 6.78E-10 2.03 112 0.052 
response to decreased oxygen levels 83 2.46E-11 2.98E-09 2.27 82 0.038 
response to oxygen levels 86 3.23E-11 3.78E-09 2.25 83 0.039 
regulation of gene expression, epigenetic 88 4.13E-11 4.72E-09 3.23 44 0.021 
embryonic placenta development 93 7.35E-11 7.95E-09 2.63 59 0.028 
peptidyl-lysine modification 103 2.47E-10 2.41E-08 2.81 50 0.023 
response to hypoxia 105 3.13E-10 2.99E-08 2.20 78 0.037 
erythrocyte homeostasis 107 5.90E-10 5.55E-08 3.22 39 0.018 
response to fluid shear stress 110 6.80E-10 6.22E-08 4.17 28 0.013 
regulation of transcription from RNA polymerase 
II promoter in response to stress 
113 1.19E-09 1.06E-07 6.02 19 0.009 
erythrocyte differentiation 115 3.44E-09 3.00E-07 3.12 37 0.017 
cellular response to peptide hormone stimulus 119 5.38E-09 4.55E-07 2.47 53 0.025 
epithelial cell differentiation involved in kidney 
development 
122 6.17E-09 5.08E-07 3.87 27 0.013 
regulation of cell shape 125 1.15E-08 9.24E-07 2.55 48 0.022 
regulation of protein complex assembly 128 1.22E-08 9.58E-07 2.05 75 0.035 





Table 4.1 Continued 
Mouse Phenotype 
   
Term Name   Binom 
Rank  
 Binom Raw 
P-Value  
  Binom FDR Q-
Val   
 Binom Fold 
Enrichment  
 Binom Observed 
Region Hits  
 Binom Region 
Set Coverage  
abnormal renal glomerulus morphology 32 6.62E-17 1.64E-14 2.17 141 0.066 
cortical renal glomerulopathies 35 1.18E-16 2.68E-14 2.78 87 0.041 
abnormal renal corpuscle morphology 37 1.70E-16 3.65E-14 2.09 149 0.070 
abnormal placenta morphology 38 3.02E-16 6.29E-14 2.01 161 0.075 
abnormal placental labyrinth vasculature 
morphology 
43 5.47E-15 1.01E-12 3.38 58 0.027 
abnormal skin physiology 47 5.14E-14 8.67E-12 2.10 123 0.058 
abnormal fibroblast migration 50 6.76E-14 1.07E-11 4.11 42 0.020 
abnormal placenta labyrinth morphology 54 4.17E-13 6.13E-11 2.41 86 0.040 
abnormal renal glomerulus basement membrane 
thickness 
55 6.33E-13 9.13E-11 4.39 36 0.017 
abnormal placenta vasculature 57 8.42E-13 1.17E-10 2.59 73 0.034 
decreased fibroblast cell migration 65 3.52E-12 4.29E-10 3.94 38 0.018 
abnormal renal glomerulus basement membrane 
morphology 
66 3.87E-12 4.65E-10 3.76 40 0.019 
decreased cell migration 67 4.94E-12 5.85E-10 3.89 38 0.018 
abnormal cell adhesion 74 1.45E-11 1.56E-09 3.40 43 0.020 
increased renal glomerulus basement membrane 
thickness 
80 7.37E-11 7.31E-09 4.08 32 0.015 
increased cell proliferation 81 8.53E-11 8.35E-09 2.10 92 0.043 
extramedullary hematopoiesis 86 1.41E-10 1.30E-08 2.43 66 0.031 
abnormal keratinocyte physiology 87 1.60E-10 1.46E-08 2.78 52 0.024 
abnormal liver parenchyma morphology 88 1.73E-10 1.56E-08 2.27 75 0.035 





Table 4.2. E9.5 highly expressed, upregualted transcription factors 
Gene e7.5 expr. e9.5 expr. log2(Fold) q-value 
Atf3 2.42 12.12 2.33 0.000164 
Batf3 9.22 32.77 1.83 0.000164 
Bbx 6.83 32.77 2.26 0.000164 
Bhlhe40 6.79 32.39 2.26 0.000164 
Cdip1 6.23 16.97 1.44 0.000164 
Cux1 4.77 16.14 1.76 0.000164 
Elf1 5.73 16.36 1.51 0.000164 
Esx1 0.81 18.11 4.48 0.000164 
Ets1 2.17 10.44 2.26 0.000164 
Gata1 1.06 10.11 3.26 0.000164 
Gcm1 0.10 14.14 8.00 0.000164 
Grhl1 3.99 12.06 1.59 0.000164 
Hmgb3 2.49 10.56 2.08 0.000164 
Id2 16.60 39.02 1.23 0.000164 
Id3 5.80 25.48 2.14 0.000164 
Irf2 5.45 12.97 1.25 0.000164 
Klf11 5.50 14.36 1.39 0.000164 
Mlxip 6.63 16.80 1.34 0.000164 
Ncor2 7.90 15.91 1.01 0.000164 
Ovol2 1.42 11.82 3.05 0.000164 
Peg3 29.34 115.88 1.98 0.000164 
Pias3 6.78 16.35 1.27 0.000164 
Plagl1 0.99 45.26 5.52 0.000164 
Pou2f3 2.55 10.71 2.07 0.000164 
Pparg 12.00 76.25 2.67 0.000164 
Rhox12 0.69 83.44 6.92 0.000164 
Rhox6 151.92 1561.59 3.36 0.000164 
Rhox9 80.86 1347.65 4.06 0.000164 
Smad5 6.84 18.02 1.40 0.000164 
Tead2 11.58 37.99 1.71 0.000164 
Tead3 12.48 31.61 1.34 0.000164 
Tfeb 5.28 37.47 2.83 0.000164 
Tulp1 0.33 10.14 4.92 0.000164 
Zbtb7b 4.21 12.74 1.60 0.000164 
Zfp362 4.26 19.09 2.16 0.000164 
Zfp655 24.85 51.28 1.05 0.000164 
Zfpm1 1.42 10.36 2.86 0.000164 
Table 4.3. Samples used for Plagl1 expression in GDM placentas 
  Males Females 






Table 4.4. List of primers used for RT-qPCR 





Plagl1 TGAAGCAATCAAGCAGGAAC CGTCATGGCTGCTTAGGCT 97.4 
Polr2a CTTTGAGGAAACGGTGGATGTC TCCCTTCATCGGGTCACTCT 95 
Human 
(hg19) 
PLAGL1 CAAGTGTGTGCAGCCTGACTGT GAACGTCTTCTCACAGTGAGCAC 104.6 
GAPDH TGGTGCTCAGTGTAGCCCAG GGACCTGACCTGCCGTCTAG 103.8 
Table 4.5. HTR-8/SVneo HISAT2 results 
Number of reads and alignment percentages for the HTR-8/SVneo RNA-seq samples 
  Read Counts % HISAT2 Alignments 
Biological Replicate Knockdown Neg. Ctrl Knockdown Neg. Ctrl 
Replicate 1 31861208 39739161 93.55 92.03 
Replicate 2 40594453 31595194 91.76 94.31 
Replicate 3 29561349 31130897 94.40 93.90 
Replicate 4 39725450 40720723 95.47 93.97 
Replicate 5 43701658 44152602 94.45 93.73 
Replicate 6 38609947 34964170 93.17 94.81 
Replicate 7 43040372 33981099 95.45 94.56 
Replicate 8 18896099 32115172 92.62 91.17 
Table 4.6. Target enhancer primers 
Enhancer Forward Reverse Vector 
COL1A1 GGTTTCTAGGCTAAGGGTGCC CCTCGGGTGTGTGGGTTG PGL4.23 LIC 
DLC1 GGGTTTTAGATTGCCACCGC AACTGGAATGAGAGGCTGCG PGL4.23 LIC 
ARHGEF3 CCTCAGTGGGCATGGCTTAA GGAGACGGAGAGAAAGCGAG PGL4.23 LIC 
IRS1 ACAAGGGTGAGCGAGCTTT CTCTTTGCTTGGCTCTGGAC PGL4.23 LIC 





CHAPTER 5.    GENERAL CONCLUSIONS 
Summary 
The placenta is a mysterious organ, generally discarded shortly after birth and forgotten. 
Throughout pregnancy the placenta protects the fetus and allows it to survive. Defects in 
placental function or development can lead to miscarriage, intrauterine growth restriction, 
preeclampsia, placenta accrete, or other diseases1–3. Not only these, but placenta dysfunction can 
result in a higher risk of diabetes, hypertension, and heart disease later in life4. Therefore, it is 
crucial to understand how the placenta functions and develops, to create better diagnostic tests 
that can identify disease early in pregnancy, and to develop better treatments and therapies once 
it has been detected. 
To this end, we used several experimental techniques to generate datasets and analyses 
that can contribute to the understanding of how the placenta functions. Though previous studies 
have looked at the correlation of ATAC-seq and RNA-seq using several timepoints, treatments, 
or tissues, our method provided a way to elucidate information from the data using a single 
timepoint and two datatsets obtained from low amounts of starting material and uncomplicated 
protocols. By analyzing the patterns of accessibility and expression, we were able to identify a 
set of repressed genes and tissue-specific genes. Not only can the ATAC-seq dataset continue to 
be used for research, but we also identified networks containing genes with poorly understood 
roles in the placenta, providing future researchers with targets for study. Through the integration 
of several ChIP-seq experiments, we were also able to annotate the placental genome, identifying 
not only regions important for transcriptional regulation, but the possible transcription factors 
binding to them. We also identified bivalent promoters at several transcription factors known to 




transcription factor, PLAGL1, as a novel regulator of placenta development. Using parallel 
studies in mouse whole placenta and a human trophoblast cell line, we identified potential roles 
for PLAGL1 in both endothelial and trophoblast cells. We were able to associate Plagl1 
expression with tube formation as well as gestational diabetes, making it an interesting candidate 
for further study.  
Overall, we generated and analyzed several datasets, in order to understand new facets of 
placental development. We discovered epigenetic patterns found near interesting genes, 
identified potential gene regulatory networks guiding placental development and function, and 
developed new methods for analyzing and integrating next generation sequencing data.  
Limitations And Future Directions 
Despite our efforts, we recognize that our studies have limitations and biases that were 
not all accounted for. The ATAC-seq data was generated shortly after the introduction of the 
method. Years of refinement and study has led to better protocols involving less cells5, less PCR 
bias6, and less contaminating mitochondrial DNA7. The data previously generated is noisy 
compared to newer datasets, therefore, it would be advantageous to generate new, cleaner data 
and perform the same analysis, which could aid in even more interesting genes being discovered.  
A potential bias arises from the combination of data from several sources. Though most 
of the histone modification ChIP-Seq data sets were generated in the same lab, not all datasets 
were. Researchers may differ in how they collect the placenta, how much of it is collected, the 
amount of extraneous tissue that is cleaned off, how long it sits in the buffer before being flash 
frozen, or even in the staging of the embryo. Although we do our best to set standards, these 
differences can lead to samples that are different in age, or placental composition. Generating 





Another potential limitation is the use of the whole placenta for experiments. The 
placenta is comprised of different cells each with unique functions, epigenetic signature and 
transcriptomic profiles. By combining information from all cells, we may lose information. 
When a gene is highly expressed in one subtype of cell and not in the others, we may see low 
averaged expression and dismiss that gene, regardless of its importance. A similar argument is 
made for accessible chromatin or histone modifications. Although we were still able to find 
interesting and biologically relevant genes in all of our studies, future work including, single-cell 
multi-omic approaches could be utilized, such as single-cell ATAC5 and RNA-seq8. For other 
datasets, using FACS to sort the various types of cells into homogeneous populations and then 
performing the experiments will help reduce the noise and biases from using a heterogeneous 
tissue.    
Lastly, we recognize that there are many areas of this research that would benefit from 
experimental validation. The high expression of tissue-specific genes, as well as their lack of 
openness could be verified with qPCR. The activity of identified enhancers, promoters and 
repressors could be determined using Dual-glow luciferase assays, while ChIP-qPCR could 
verify the predicted transcription factors controlling enhancer regions. Protein data could have 
been used to check PLAGL1 knockdown and binding to predicted regions, however, an adequate 
antibody is not available for such projects at this time. Also, the effects of PLAGL1 knockdown 
were variable, perhaps due to off targets effects. More research needs to be done into the siRNAs 
used to know if they are knocking down unintended targets. Despite these limitations, the 
information presented here contributes to our knowledge of the placenta, and the datasets 
generated will continue to provide researchers with information that can be combined with their 





The previously described research was done using the e9.5 midgestation placenta. There 
are several other timepoints to be explored to get a full picture of how the genetic landscape of 
the placenta changes throughout development. Additional techniques could also be applied, 
including DNA Hi-C9 to establish a connection between promoters and enhancers, STARR-seq10 
to identify active enhancers genome-wide, ChIP for other histone modifications11, Ribo-seq12 to 
identify transcripts that are being translated, or proteomics-based methods. The ultimate goal is 
to apply our findings to contribute to knowledge of the gene-regulatory networks important for 
human placental function and development. Therefore, all findings need to be validated in the 
human placenta as well. 
Overall, we were able to develop a new method for ATAC-seq and RNA-seq integration 
and analysis, annotate regulatory regions in the midgestation mouse placenta, provide a method 
for identifying TFs with a role in enhancer regulation, and discover potentially novel roles for 
PLAGL1 contributing to placental dysfunction. This work has benefitted not only the placenta 
community, but the bioinformatic community as well. The datasets and findings have contributed 
to our knowledge of genetic regulation of the placenta and will continue to help researchers in 
our lab and others uncover the mysteries of placental development and function, helping to 
understand placental disease and contribute to maternal and fetal health throughout pregnancy 
and beyond. 
References 
1.  Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: Implications for 
the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 
2003;69(1):1-7. doi:10.1095/biolreprod.102.014977 
2.  Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: involvement of 





3.  Khong TY. The pathology of placenta accreta, a worldwide epidemic. J Clin Pathol. 
2008;61(12):1243-1246. doi:10.1136/jcp.2008.055202 
4.  Godfrey KM. The role of the placenta in fetal programming - A review. Placenta. 
2002;23(SUPPL. 1). doi:10.1053/plac.2002.0773 
5.  Buenrostro JD, Wu B, Litzenburger UM, et al. Single-cell chromatin accessibility reveals 
principles of regulatory variation. Nature. 2015;523(7561):486-490. 
doi:10.1038/nature14590 
6.  Halstead MM, Kern C, Saelao P, et al. Systematic alteration of ATAC-seq for profiling 
open chromatin in cryopreserved nuclei preparations from livestock tissues. Sci Rep. 
2020;10(1):1-12. doi:10.1038/s41598-020-61678-9 
7.  Rickner HD, Niu SY, Cheng CS. ATAC-seq assay with low mitochondrial dna 
contamination from primary human CD4+ T lymphocytes. J Vis Exp. 2019;(145). 
doi:10.3791/59120 
8.  Tang F, Barbacioru C, Wang Y, et al. mRNA-Seq whole-transcriptome analysis of a 
single cell. Nat Methods. 2009;6(5):377-382. doi:10.1038/nmeth.1315 
9.  Belton JM, McCord RP, Gibcus JH, Naumova N, Zhan Y, Dekker J. Hi-C: A 
comprehensive technique to capture the conformation of genomes. Methods. 
2012;58(3):268-276. doi:10.1016/j.ymeth.2012.05.001 
10.  Arnold CD, Gerlach D, Stelzer C, Boryń ŁM, Rath M, Stark A. Genome-wide quantitative 
enhancer activity maps identified by STARR-seq. Science (80- ). 2013;339(6123):1074-
1077. doi:10.1126/science.1232542 
11.  Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis 
of 111 reference human epigenomes. Nature. 2015;518(7539):317-329. 
doi:10.1038/nature14248 
12.  Ingolia NT, Ghaemmaghami S, Newman JRS, Weissman JS. Genome-wide analysis in 
vivo of translation with nucleotide resolution using ribosome profiling. Science (80- ). 
2009;324(5924):218-223. doi:10.1126/science.1168978 
 
